Page last updated: 2024-11-04

sotalol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sotalol is a nonselective beta blocker with class III antiarrhythmic properties. It is used to treat certain types of irregular heartbeats (arrhythmias). Sotalol is available as an oral tablet and is typically taken twice a day. The exact mechanism of action of sotalol is not fully understood, but it is believed to block the beta-adrenergic receptors in the heart, which slows the heart rate and reduces the force of contractions. Sotalol also prolongs the QT interval on an electrocardiogram (ECG), which is a measure of the time it takes for the ventricles of the heart to repolarize. This effect may be responsible for sotalol's antiarrhythmic activity. Sotalol is synthesized by a multi-step process that involves the reaction of a substituted benzamide with a 1,3-dichloropropane derivative. The synthesis is relatively complex and involves several steps, including amination, alkylation, and cyclization. Sotalol is an important drug for the treatment of certain types of arrhythmias, and it is studied extensively to improve its safety and efficacy. It is also being investigated for its potential use in the treatment of other cardiovascular conditions, such as heart failure and hypertension. Sotalol has a number of side effects, including fatigue, dizziness, and shortness of breath. It can also cause serious adverse effects, such as low blood pressure, slow heart rate, and heart block. Sotalol should not be used by people with certain medical conditions, such as asthma, heart failure, or severe bradycardia.'

Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5253
CHEMBL ID471
CHEBI ID63622
SCHEMBL ID16407
MeSH IDM0020177

Synonyms (90)

Synonym
AC-19021
AB00514715-09
AB00514715-10
BRD-A33168282-003-03-2
methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-
n-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide
4'-(1-hydroxy-2-isopropylaminoethyl)methanesulfonanilid
methanesulfonamide, n-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-
sotalol [inn:ban]
sotalolum [inn-latin]
ccris 4204
PRESTWICK3_000966
.beta.-cardone
BPBIO1_001069
chembl471 ,
cid_66245
bdbm25762
sotalol,(+)
sotalol,(-)
AB00514715
sotalol
C07309
3930-20-9
4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
DB00489
beta-cardone
NCGC00024899-03
PRESTWICK1_000966
PRESTWICK0_000966
SPBIO_002892
BSPBIO_000971
LOPAC0_001055
PRESTWICK2_000966
NCGC00024899-02
n-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide
L013427
HMS2089K09
NCGC00015919-05
chebi:63622 ,
c07aa07
darob mite
dl-sotalol
sotalol (inn)
darob mite (tn)
D08525
n-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
NCGC00015919-04
dtxsid0023589 ,
tox21_110261
dtxcid303589
cas-3930-20-9
CCG-205132
NCGC00015919-03
NCGC00015919-06
NCGC00015919-07
a6d97u294i ,
unii-a6d97u294i
sotalolum
(+-)-sotalol
AKOS015897340
gtpl7297
n-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
4'-(1-hydroxy-2-(isopropylamino)ethyl)methanesulfonanilide
dl-4-(2-isopropylamino-1-hydroxyethyl)methanesulfonanilide
sotalol [vandf]
sotalol [mi]
sotalol [who-dd]
sotalol [inn]
n-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)methanesulfonamide
(+/-)-sotalol
SCHEMBL16407
n-{4-[1-hydroxy-2-(isopropylamino)ethyl]phenyl}methanesulfonamide
n-(4-(1-hydroxy-2-(isopropylamino)ethyl)phenyl)methanesulfonamide
4'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide
4'-[1-hydroxy-2-(isopropylamino)ethyl]metahnesulfonanilide
n-(4-[1-hydroxy-2-(isopropylamino)ethyl]phenyl)methanesulfonamide #
4'-[1-hhydroxy-2-(isopropylamino)ethyl]methanesulfonanilide
AB00514715_11
AB00514715_12
methanesulfonamide, n-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-
SBI-0051025.P002
Q413591
BRD-A33168282-003-06-5
SDCCGSBI-0051025.P003
NCGC00015919-18
NCGC00015919-14
EN300-7382649
sotalolo
sotalolum (inn-latin)
n-(4-(1-hydroxy-2-(propan-2-ylamino)ethyl)phenyl)methanesulfonamide

Research Excerpts

Overview

Oral sotalol is a class III antiarrhythmic commonly used for the maintenance of sinus rhythm in patients with atrial fibrillation (AF) It is a nonselective beta-adrenergic blocking agent without intrinsic sympathomimetic activity.

ExcerptReferenceRelevance
"Oral sotalol is a class III antiarrhythmic commonly used for the maintenance of sinus rhythm in patients with atrial fibrillation (AF). "( Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias.
Bunch, TJ; Dechand, J; Feuerborn, ML; Freedman, RA; Groh, C; Navaravong, L; Ranjan, R; Steinberg, BA; Torre, M; Vadlamudi, RS; Varela, D, 2023
)
1.67
"Sotalol is a nonselective β-adrenergic receptor antagonist with class III antiarrhythmic properties that has been mostly used for atrial fibrillation treatment and suppressing recurrent ventricular tachyarrhythmias."( The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
Alvarez, C; Augustin, N; Kluger, J, 2023
)
1.93
"Sotalol is an anti-arrhythmic drug commonly used for the treatment of pathologic tachyarrhythmias in dogs. "( Inotropic and chronotropic effects of sotalol in healthy dogs.
LeBlanc, NL; Scollan, KF; Treseder, JR, 2019
)
2.23
"Sotalol is an important antiarrhythmic drug in the pediatric population. "( Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
Abrams, DJ; Alexander, ME; Bevilacqua, LM; Bezzerides, VJ; Chandler, SF; Chu, E; DeWitt, ES; Mah, DY; Triedman, JK; Walsh, EP; Whitehill, RD, 2020
)
2.28
"Sotalol is a class III antiarrhythmic drug commonly used in various arrhythmia treatments. "( Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats.
Dinçsoy, B; Erdemb, A; Gedikli, E; Özgür Barış, V, 2021
)
2.33
"Sotalol is a non-selective beta-adrenergic blocking agent without intrinsic sympathomimetic activity. "( The Use of Intravenous Sotalol in Cardiac Arrhythmias.
Kovoor, P; Lakkireddy, DJ; Samanta, R; Thiagalingam, A; Turner, C, 2018
)
2.23
"Sotalol is an attractive alternative antiarrhythmic to amiodarone in this younger patient population, given the latter's toxicity profile, but it may have proarrhythmic effects."( Efficacy and adverse effects of sotalol in adults with congenital heart disease.
Celermajer, DS; Cordina, RL; McGuire, MA; Moore, BM, 2019
)
1.52
"Sotalol is a commonly used antiarrhythmic drug that may alter ventricular function."( Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias.
Bélanger, C; Gunther-Harrington, CT; Kaplan, JL; Mueller, MS; Nishimura, S; Oldach, MS; Stern, JA; Visser, LC, 2018
)
2.2
"IV sotalol is an effective antiarrhythmic option for pediatric patients and may be an excellent agent for acute termination of active arrhythmias. "( Early experience with intravenous sotalol in children with and without congenital heart disease.
Asaki, SY; de la Uz, CM; Kim, JJ; Lam, WW; Landstrom, AP; Miyake, CY; Niu, MC; Patel, R; Rusin, CG; Schneider, AE; Valdés, SO, 2018
)
1.38
"Sotalol is a bêta-blocker and class 3 anti-arrhythmic. "( [Torsade de pointe resulting from a drug interaction between sotalol and ciprofloxacin].
Devaux, F; Fillet, M; Krzesinski, F, 2019
)
2.2
"Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF). "( Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease.
Al-Khatib, SM; Allen-LaPointe, N; Anstrom, KJ; Daubert, JP; DeWald, T; Horton, JR; Lokhnygina, Y; Peterson, ED; Piccini, JP; Shaw, LK; Steinberg, BA; Thomas, K; Wojdyla, DM, 2014
)
2.15
"Sotalol is a class III antiarrhythmic agent that is highly effective for tachyarrhythmias in adults, but its efficacy in patients with congenital heart disease (CHD) remains unclear. "( Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease.
Kamakura, S; Kurosaki, K; Miyazaki, A; Ohuchi, H; Yagihara, T; Yamada, O, 2008
)
2.1
"dl-Sotalol (SOT) is a β-blocker commonly used in the rhythm-control treatment of atrial fibrillation."( Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.
Antzelevitch, C; Gibson, JK; Lynch, JJ; Pourrier, M; Sicouri, S, 2012
)
1.11
"Sotalol is a potent antiarrhythmic often used in patients with atrial fibrillation. "( A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist.
Chua, T; Hsu, LF; Kam, RM; Tan, HH; Teo, WS, 2003
)
2.1
"Sotalol is a potent antiarrhythmic agent in the treatment of fetal tachycardia. "( Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics.
Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Ruskamp, JM; Stoutenbeek, P; Ververs, FF; Visser, GH, 2003
)
2.04
"Sotalol was shown to be a selective beta antagonist in this system, blocking excitation evoked by the beta agonist isoproterenol while having no effect on inhibition elicited by the alpha agonist clonidine; however, the potency of sotalol (Ki = 3.5 microM) was considerably less than that of timolol (Ki = 50 nM)."( Hippocampal noradrenergic responses in vivo and in vitro. Characterization of alpha and beta components.
Dunwiddie, TV; Hoffer, BJ; Mueller, AL; Palmer, MR, 1982
)
0.99
"Sotalol is a beta-adrenergic blocker that also prolongs action potential duration and myocardial refractoriness over the short term (class III effect). "( Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase.
Brachmann, J; Cobbe, SM; Hoffman, E; Kübler, W; Ritzenhoff, A; Senges, J, 1983
)
2.11
"Sotalol is a nonselective beta-adrenoceptor antagonist which prolongs cardiac repolarisation independently of its antiadrenergic action (class III antiarrhythmic properties). "( Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
Fitton, A; Sorkin, EM, 1993
)
3.17
"Sotalol is a beta-adrenergic blocking agent with additional class III antiarrhythmic properties. "( Efficacy and proarrhythmia of oral sotalol in pediatric patients.
Kallfelz, HC; Lehmann, C; Paul, T; Pfammatter, JP, 1995
)
2.01
"Sotalol is an antiarrhythmic medication that has properties of both a beta-blocker and a class III agent and has been used safely and effectively to treat arrhythmias of multiple mechanisms in pediatric patients. "( Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome.
Lulu, JA; Saul, JP; Tanel, RE; Walsh, EP, 1995
)
3.18
"Sotalol is a beta-blocking drug devoid of membrane stabilizing properties, as well as intrinsic sympathomimetic actions, or cardioselectivity. "( Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound".
Claudel, JP; Touboul, P, 1995
)
3.18
"Sotalol is a water-soluble, nonselective, beta-adrenergic blocker that was recently approved in oral form in the United States for the treatment of ventricular arrhythmias that are judged to be life-threatening. "( Sotalol: a new beta-adrenergic blocker for ventricular arrhythmias.
Cavusoglu, E; Frishman, WH,
)
3.02
"Sotalol is an effective atrial antiarrhythmic drug with class III and beta-adrenergic blocking properties."( Aggravation of postcardioversion atrial dysfunction by sotalol.
Falk, RH; Pollak, A, 1995
)
1.26
"Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties. "( Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995
)
2.11
"d,l-Sotalol is a racemic drug composed of equimolar amounts of d-(+)-sotalol and l-(-)-sotalol. "( Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
Funck-Brentano, C, 1993
)
1.1
"Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential. "( Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery.
Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994
)
2.01
"Sotalol (STL) is a chiral beta-adrenergic blocking drug, which is useful clinically as the racemate in treating hypertension, and is also useful as a class III antiarrhythmic when administered as the pure S-enantiomer. "( Stereospecific evaluation of sotalol pharmacokinetics in a rat model: evidence suggesting an enantiomeric interaction.
Carr, RA; Foster, RT; Pasutto, FM, 1994
)
2.02
"Sotalol is a beta-blocker with additional class III activity."( Class III antiarrhythmics in overdose. Presenting features and management principles.
Holt, DW; Leatham, EW; McKenna, WJ, 1993
)
1.01
"Sotalol is a class III antiarrhythmic that prolongs the action potential and refractoriness of cardiac tissue and has potent nonselective beta-blocking activity."( Sotalol: a new class III antiarrhythmic agent.
Zanetti, LA, 1993
)
2.45
"Sotalol is a class III antiarrhythmic drug with additional beta-blocker activity that has been shown to be effective in supraventricular and ventricular arrhythmias. "( Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
Boone, J; Kerr, CR; Mohama, R; Yeung-Lai-Wah, JA; Young, GD, 1994
)
2.11
"Sotalol is a novel antiarrhythmic agent combining beta-adrenergic-antagonist actions with the ability to increase cardiac repolarization and refractoriness. "( Sotalol.
Hohnloser, SH; Woosley, RL, 1994
)
3.17
"Sotalol is a racemic compound with Class II (beta-blocking properties) and Class III (prolonged action potential) antiarrhythmic activity. "( Sotalol: a breakthrough antiarrhythmic?
McCollam, PL; Nappi, JM, 1993
)
3.17
"IV d-sotalol appears to be an effective antiarrhythmic agent."( Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias.
Beyer, T; Brachmann, J; Enders, B; Kübler, W; Montero, M; Schöls, W, 1993
)
1
"Sotalol is an antiarrhythmic agent with combined class II and III properties. "( Clinical pharmacokinetics of sotalol.
Hanyok, JJ, 1993
)
2.02
"Sotalol is a competitive beta adrenoceptor antagonist devoid of membrane-stabilizing activity and intrinsic sympathomimetic activity that has no preferential actions on beta 1 or beta 2 responses. "( Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol.
Antonaccio, MJ; Gomoll, A, 1993
)
1.96
"Sotalol is a unique antiarrhythmic drug that combines beta-blocking effects with actions to prolong action potential duration. "( Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
Campbell, RW; Furniss, SS, 1993
)
2
"Sotalol is a unique compound with several potential antiarrhythmic mechanisms, including beta blockade (class II activity), action potential duration prolongation (class III activity), and possibly reduction of QT dispersion. "( Evolving role of sotalol in the management of ventricular tachyarrhythmias.
McGovern, BA; O'Callaghan, PA, 1996
)
2.08
"Sotalol is a noncardioselective beta-blocking agent with additional class III antiarrhythmic properties (action potential duration prolongation). "( New antiarrhythmic drug in pediatric use: sotalol.
Paul, T; Pfammatter, JP,
)
1.84
"Sotalol (STL) is an amphoteric, chiral beta-adrenergic blocking drug useful in the treatment of both hypertension and ventricular arrhythmias. "( Influence of cimetidine coadministration on the pharmacokinetics of sotalol enantiomers in an anaesthetized rat model: evidence supporting active renal excretion of sotalol.
Carr, RA; Foster, RT; Pasutto, FM, 1996
)
1.97
"d,l-Sotalol is a noncardioselective beta-blocker that has class III antiarrhythmic activity. "( Is oral sotalol effective in converting atrial fibrillation to sinus rhythm?
Ferreira, E; Gin, K; Sunderji, R,
)
1.12
"Sotalol is a beta-adrenoreceptor blocking drug, the clinical efficacy of which has been linked up to its negative chrono- and inotropic effects and its hypotensive action. "( Thrombolytic activity of beta-adrenolytic drug, sotalol.
Gryglewski, RJ; Korbut, R; Marcinkiewicz, E; Swies, J, 1998
)
2
"Sotalol is a betablocker with additional antiarrythmic properties. "( [Sotalol--atrial fibrillation, reduced renal function and sudden death].
Bathen, J; Madsen, S, 1998
)
2.65
"D,l-sotalol is an important antiarrhythmic agent to prevent recurrences of sustained ventricular tachyarrhythmias (VT/VF). "( Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999
)
1.09
"Sotalol appears to be a preferred drug for use with implantable defibrillators; unlike some other agents (eg, amiodarone) it does not elevate and, indeed, may lower defibrillation threshold."( Sotalol: An important new antiarrhythmic.
Anderson, JL; Prystowsky, EN, 1999
)
2.47
"D,l sotalol is an antiarrhythmic widely used for treating ventricular excitability, especially ventricular tachycardia (VT). "( [Action of sotalol on high-amplification electrocardiogram].
Beurrier, D; Brembilla-Perrot, B; Claudon, O; Houriez, P; Louis, P; Preiss, JP; Terrier de la Chaise, A, 2000
)
1.25
"D-Sotalol is a weak beta-adrenoceptor antagonist and may also be a positive inotrope."( D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?
Brown, L; Doggrell, SA, 2000
)
1.59
"Sotalol is a beta-adrenoceptor blocking drug which also has class III antiarrhythmic properties via Ikr channel blockade."( Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol.
Danielsson, BR; Sköld, AC, 2001
)
1.26
"Sotalol is a safe and effective agent for control of heart rate in digitalized patients with atrial fibrillation. "( Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study.
Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001
)
3.2
"Sotalol is a beta-adrenergic receptor blocking and anti-arrhythmic agent."( [Chronic hepatitis ascribed to the use of sotalol].
Janssens, AR; Kootte, AM; Ouwehand, DK; van Leeuwen, AM, 2001
)
1.3
"Sotalol is a new beta-adrenoceptor blocking drug without membrane stabilizing activity, without intrinsic sympathomimetic activity and with a low cardio-depressive effect. "( [Treatment of hypertension with Sotalol (author's transl)].
Fillastre, JP; Gauthier, A; Godin, M; Joire, JE,
)
1.86
"Sotalol is a pure beta-adrenergic receptor antagonist. "( Long-term sotalol therapy in patients with arrhythmias.
Berman, E; Simon, A,
)
1.98
"Sotalol (Sotacor) is a beta-adrenergic receptor blocking agent, which in addition possesses class III anti-arrhythmic properties. "( The efficacy of sotalol in suppressing ventricular ectopic beats.
Cartoon, J; Goldman, aP; Myburgh, DP; Schamroth, JM, 1979
)
2.05
"DL-Sotalol is a unique antiarrhythmic agent combining potent beta-blocking properties with the propensity to prolong cardiac repolarization in all myocardial tissues. "( Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
Singh, BN, 1992
)
1.2
"Sotalol is a unique beta-blocker that prolongs repolarization. "( Efficacy and safety of sotalol in patients with complex ventricular arrhythmias.
Hohnloser, SH; Just, H; Klingenheben, T; van de Loo, A; Zabel, M, 1992
)
2.04
"Sotalol is a beta-blocker with class III antiarrhythmic properties that has recently been used in children for the treatment of supraventricular and ventricular arrhythmias. "( Electrophysiologic effects of sotalol on the immature mammalian heart.
Chartrand, C; Davignon, A; Ducharme, G; Fournier, A; Houyel, L, 1992
)
2.01
"Sotalol is a beta blocker with class III activity. "( Effectiveness of oral sotalol for treatment of pediatric arrhythmias.
Fournier, A; Maragnès, P; Tipple, M, 1992
)
2.04
"Sotalol appears to be an effective and well tolerated agent for treatment of complex ventricular ectopic activity, even in the setting of compromised cardiac function."( Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.
Hohnloser, SH; Just, H; Krause, T; Zabel, M, 1992
)
1.24
"Sotalol is a unique beta-blocking drug, possessing significant class III antiarrhythmic activity. "( Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias.
Anastasiou-Nana, MI; Anderson, JL; Freedman, RA; Gilbert, EM; Keefe, DL; MacNeil, DJ; Miller, RH; Saksena, S; Singh, S, 1991
)
2.05
"Sotalol is an effective, safe drug for the treatment of supraventricular tachycardias in early infancy."( Efficacy and safety of oral sotalol in early infancy.
Sandor, G; Tipple, M, 1991
)
1.3
"Sotalol is a unique beta blocker in not only antagonizing sympathetic stimulation competitively, but also in exerting a potent antiarrhythmic effect by prolonging repolarization."( Is class III antiarrhythmic activity important?
Singh, BN, 1990
)
1
"Sotalol is a valuable antiarrhythmic drug for reentrant ventricular tachycardia."( Efficacy of oral sotalol in reentrant ventricular tachycardia.
Haitus, B; Jardine, R; Millar, RN; Obel, IW, 1990
)
1.34
"Sotalol is a nonselective, water-soluble beta-adrenoceptor antagonist with no membrane-stabilizing activity or intrinsic sympathomimetic activity. "( Pharmacology, pharmacodynamics and pharmacokinetics of sotalol.
Antonaccio, MJ; Gomoll, A, 1990
)
1.97
"Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-Williams class III antiarrhythmic agents in experimental models. "( Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses.
Anderson, JL; Askins, JC; Freedman, RA; Gilbert, EM; Haft, LR; Keefe, DL; Lessem, JN; Mason, JW; Miller, RH; Somberg, JC, 1986
)
2.03
"Sotalol is a beta blocker that has also been reported to exert class III antiarrhythmic effects. "( Comparisons of the electrophysiological effects of intravenous sotalol and propranolol on the immature mammalian heart.
Gelband, H; McCormack, J; Pickoff, AS; Stolfi, A; Villafane, J; Xu, H, 1989
)
1.96
"Sotalol is a beta-blocker which also prolongs repolarization. "( Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia.
Grace, M; Klinke, WP; Kubac, G, 1988
)
1.99
"Sotalol is a nonselective beta-adrenergic blocking agent with Vaughn-Williams class III activity. "( Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Constantin, L; Hopson, R; Kienzle, MG; Martins, JB; McCue, ML; Wendt, DJ, 1988
)
2.02
"Sotalol is a beta-blocking agent endowed with class III electrophysiological properties. "( [Sotalol-induced torsades de pointe in the conscious dog with atrioventricular block. Role of hypokalemia].
Cheymol, G; Chezalviel, F; Davy, JM; Ertzbischoff, O; Lainée, P; Motte, G; Poirier, JM; Weissenburger, J, 1988
)
2.63
"Sotalol is a beta-adrenoceptor blocking agent devoid of intrinsic sympathomimetic activity, membrane stabilising actions and cardioselectivity. "( Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Deedwania, P; Nademanee, K; Singh, BN; Sorkin, EM; Ward, A, 1987
)
3.16
"Sotalol is a non-selective beta-adrenergic blocking agent with class III antiarrhythmic properties. "( The effect of sotalol on exercise-induced ventricular arrhythmias.
Glogar, D; Petzl, DH; Probst, P; Schuster, E, 1988
)
2.08
"Sotalol is a beta-adrenergic blocking agent that prolongs the duration of the cardiac action potential in humans, without affecting the upstroke velocity of depolarization. "( Electrophysiologic effects of d-sotalol in humans.
Garan, H; McComb, JM; McGovern, B; McGowan, JB; Ruskin, JN, 1987
)
2
"D-sotalol appears to be an effective antiarrhythmic drugs and appears to be well tolerated."( The antiarrhythmic effects of d-sotalol.
Crocker, K; Schwartz, J; Somberg, JC; Wynn, J, 1987
)
1.11
"Sotalol is a nonselective beta-receptor antagonist that prolongs action potential duration and refractoriness in vitro at higher concentrations than those associated with heart rate slowing. "( Concentration-dependent pharmacologic properties of sotalol.
Bergstrand, RH; Duff, HJ; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Woosley, RL, 1986
)
1.96
"Dl-sotalol is a specific beta-adrenergic blocking agent that markedly lengthens cardiac action potential duration. "( Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics.
Ikeda, N; Kannan, R; Kato, R; Singh, BN; Yabek, SM, 1986
)
1.13
"Sotalol is a unique beta-blocker that lengthens cardiac repolarization and effective refractory period (ERP). "( Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Feld, G; Hendrickson, J; Nademanee, K; Singh, BN; Singh, PN, 1985
)
1.97

Effects

Sotalol has a mild negative inotropic effect in healthy dogs. Sotalol also has a weak anti-aggregatory activity (IC50 approximately 500-1000 microM) in human platelet rich plasma.

Sotalol has the potential to lengthen the Q-T interval and to initiate severe arrhythmias such as ventricular tachycardia or fibrillation. Sotalol also has a weak anti-aggregatory activity (IC50 approximately 500-1000 microM) in human platelet rich plasma (PRP)

ExcerptReferenceRelevance
"IV sotalol loading has a safety profile that is similar to oral sotalol. "( Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay.
Arora, R; Charron, J; Chicos, A; Fugaro, D; Gao, X; Gay, H; Kaplan, R; Kim, S; Knight, BP; Lin, AC; Liu, AY; Lohrmann, G; Passman, R; Patil, K; Pfenniger, A; Spoolstra, S; Verma, N, 2023
)
1.81
"Sotalol has a mild negative inotropic effect in healthy dogs based on standard echocardiographic measurements. "( Inotropic and chronotropic effects of sotalol in healthy dogs.
LeBlanc, NL; Scollan, KF; Treseder, JR, 2019
)
2.23
"IV sotalol has a rapid onset of action with linear pharmacokinetics."( Intravenous Sotalol: An Under Used Treatment Strategy.
Kerin, NZ, 2018
)
1.37
"Sotalol has an important indication for the management of ventricular tachyarrhythmias."( Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
Campbell, RW; Furniss, SS, 1993
)
1.28
"Sotalol also has a weak anti-aggregatory activity (IC50 approximately 500-1000 microM) in human platelet rich plasma (PRP)."( Thrombolytic activity of beta-adrenolytic drug, sotalol.
Gryglewski, RJ; Korbut, R; Marcinkiewicz, E; Swies, J, 1998
)
1.28
"Sotalol has a rapid onset of action, allowing it to be efficacious when used orally shortly after surgery."( Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents.
Morady, F, 1999
)
1.02
"Sotalol has a virtually unique antiarrhythmic profile in that it combines the properties of the Class II beta-blocking agents with the Class III properties that prolong repolarization. "( Mechanism of action of sotalol in supraventricular arrhythmias.
Brugada, J; Brugada, P; Farré, J; Smeets, JL, 1990
)
2.03
"Sotalol has an additional propensity for blocking beta receptors; therefore, its net effects in controlling arrhythmias result from its beta-blocking actions as well as lengthening the refractory period of cardiac muscle."( Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
Singh, BN, 1990
)
1.23
"IV sotalol loading has a safety profile that is similar to oral sotalol. "( Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay.
Arora, R; Charron, J; Chicos, A; Fugaro, D; Gao, X; Gay, H; Kaplan, R; Kim, S; Knight, BP; Lin, AC; Liu, AY; Lohrmann, G; Passman, R; Patil, K; Pfenniger, A; Spoolstra, S; Verma, N, 2023
)
1.81
"Sotalol has been shown to reduce defibrillation energy requirements and reduce shocks from implantable cardioverter-defibrillators."( The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
Alvarez, C; Augustin, N; Kluger, J, 2023
)
1.93
"Sotalol has a mild negative inotropic effect in healthy dogs based on standard echocardiographic measurements. "( Inotropic and chronotropic effects of sotalol in healthy dogs.
LeBlanc, NL; Scollan, KF; Treseder, JR, 2019
)
2.23
"Sotalol therapy has been indicated for the management of supraventricular arrhythmias, refractory life threatening ventricular arrhythmias and atrial fibrillation/flutter."( The Use of Intravenous Sotalol in Cardiac Arrhythmias.
Kovoor, P; Lakkireddy, DJ; Samanta, R; Thiagalingam, A; Turner, C, 2018
)
1.51
"IV sotalol has a rapid onset of action with linear pharmacokinetics."( Intravenous Sotalol: An Under Used Treatment Strategy.
Kerin, NZ, 2018
)
1.37
"DL-Sotalol has class III antiarrhythmic activity through prolongation of the repolarization phase of the action potential as well as beta-adrenoceptor-blocking properties. "( Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
Fraedrich, G; Hasenfuss, G; Holubarsch, C; Just, H; Pieske, B; Posival, H; Ruf, T; Schneider, R, 1995
)
1.17
"d-Sotalol has pharmacokinetic properties that resemble those of the racemate."( Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
Advani, SV; Singh, BN, 1995
)
1.08
"Sotalol has been found to be effective in controlling life-threatening ventricular arrhythmias, including sustained ventricular tachycardia, ventricular fibrillation, and premature ventricular complexes."( Sotalol: a new class III antiarrhythmic agent.
Zanetti, LA, 1993
)
2.45
"Sotalol has an important indication for the management of ventricular tachyarrhythmias."( Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
Campbell, RW; Furniss, SS, 1993
)
1.28
"Sotalol overdose has special features because this beta-blocker has the potential to lengthen the Q-T interval and to initiate severe arrhythmias such as ventricular tachycardia or fibrillation. "( Sotalol poisoning associated with asystole.
Alderfliegel, F; Demaeyer, P; Kahn, RJ; Leeman, M, 1993
)
3.17
"Sotalol has not been widely studied in postinfarct patients; one trial indicated that the drug did reduce total mortality but the difference did not reach statistical significance."( Expanding indications for the use of Class III agents in patients at high risk for sudden death.
Singh, BN, 1995
)
1.01
"2. Sotalol has no relevant negative inotropic effect, at least not in association with captopril."( Hemodynamic performances in patients treated with sotalol after electrical cardioversion of atrial fibrillation.
Dan, GA; Gonţa, A,
)
0.9
"Sotalol also has a weak anti-aggregatory activity (IC50 approximately 500-1000 microM) in human platelet rich plasma (PRP)."( Thrombolytic activity of beta-adrenolytic drug, sotalol.
Gryglewski, RJ; Korbut, R; Marcinkiewicz, E; Swies, J, 1998
)
1.28
"Sotalol has been associated with a decrease in defibrillation threshold in both animal and in clinical studies, whereas amiodarone has been associated with variable effects in animal models and an increase in defibrillation threshold in clinical studies."( Interactions between implantable cardioverter-defibrillators and class III agents.
Marchlinski, FE; Movsowitz, C, 1998
)
1.02
"Sotalol has been commonly used in cases of angina pectoris and hypertension."( [Sotalol--atrial fibrillation, reduced renal function and sudden death].
Bathen, J; Madsen, S, 1998
)
1.93
"Sotalol has a rapid onset of action, allowing it to be efficacious when used orally shortly after surgery."( Prevention of atrial fibrillation in the postoperative cardiac patient: significance of oral class III antiarrhythmic agents.
Morady, F, 1999
)
1.02
"D-Sotalol also has no effect on the K(ATP) channel, which is activated in ischaemia to shorten the action potential."( D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?
Brown, L; Doggrell, SA, 2000
)
1.59
"Sotalol has Class II and III antiarrhythmic effects. "( Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol.
Madrid, AH; Maŕin Huerta, EM; Mestre, JL; Moro, C; Novo, L, 1992
)
1.95
"Sotalol has a virtually unique antiarrhythmic profile in that it combines the properties of the Class II beta-blocking agents with the Class III properties that prolong repolarization. "( Mechanism of action of sotalol in supraventricular arrhythmias.
Brugada, J; Brugada, P; Farré, J; Smeets, JL, 1990
)
2.03
"Sotalol has an additional propensity for blocking beta receptors; therefore, its net effects in controlling arrhythmias result from its beta-blocking actions as well as lengthening the refractory period of cardiac muscle."( Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
Singh, BN, 1990
)
1.23
"d-Sotalol has not been studied extensively in humans."( Electrophysiologic effects of d-sotalol in humans.
Garan, H; McComb, JM; McGovern, B; McGowan, JB; Ruskin, JN, 1987
)
1.11

Actions

Sotalol did not suppress the reperfusion VF in halothane anesthetized animals. The sotalol-induced increase in action potential duration and development of early after depolarizations may, therefore, be abated by combination with drugs that either block cardiac sodium channels or that increase membrane potassium conductance.

ExcerptReferenceRelevance
"Sotalol did not produce any change in blood pressure, and propranolol raised the blood pressure."( Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
Goto, K; Kasuya, Y; Obase, H; Shigenobu, K; Tatsuno, H, 1977
)
0.98
"d-Sotalol did not suppress the reperfusion VF in halothane anesthetized animals, nor did it show proarrhythmic effects."( Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.
Awaji, T; Haruno, A; Hashimoto, K; Hirasawa, A; Wu, Z; Xue, Y, 1995
)
1.09
"Sotalol may inhibit IK.ACh by the blockade of the atrial muscarinic receptors, whereas E-4031 and MS-551 may inhibit the current not only by blocking the muscarinic receptors but also by depressing the function of the K+ channel itself and/or G proteins. "( Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
Hara, Y; Masuda, Y; Mori, K; Nakaya, H; Saito, T, 1995
)
1.73
"Sotalol's ability to suppress ventricular ectopy is similar to that of class I agents and better than that of standard beta-blockers."( Sotalol: An important new antiarrhythmic.
Anderson, JL; Prystowsky, EN, 1999
)
2.47
"Sotalol produced a lower heart rate than metoprolol only at submaximal exercise (116 +/- 9 bpm for sotalol vs 125 +/- 11 bpm for metoprolol, P < 0.001)."( Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study.
Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001
)
2.47
"Sotalol blunted the increase in ventricular premature beat frequency on ambulatory monitoring which occurred with atenolol, although direct comparison of arrhythmia frequency between the groups receiving atenolol and sotalol revealed no significant difference."( A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction.
Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988
)
1.26
"The sotalol-induced increase in action potential duration and development of early after depolarizations may, therefore, be abated by combination with drugs that either block cardiac sodium channels or that increase membrane potassium conductance."( Modulation of the effects of sotalol on Purkinje strand electromechanical characteristics.
Lathrop, DA; Varró, A, 1989
)
1.05

Treatment

Sotalol treatment led to a marked reduction in arrhythmic events. Treatment with sotalol or mexiletine-atenolol was well tolerated and efficacious. Sotalol prolonged AERP, even after atrial electrical remodeling had developed.

ExcerptReferenceRelevance
"d,l-Sotalol treatment showed lower AF inducibility and shorter AF duration at 4 weeks."( d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing.
Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009
)
1.39
"d,l-Sotalol treatment prolonged AERP, even after atrial electrical remodeling had developed, and prevented AF perpetuation without affecting downregulated expression of L-type Ca(2+) channel alpha1c and Kv4.3 mRNA in an ATP-induced canine AF model."( d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing.
Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009
)
1.47
"Oral sotalol treatment was started after unsuccessful DC cardioversion and given at least 7 days before renewed cardioversion."( Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.
Frick, M; Nergärdh, A; Nordlander, R, 2006
)
1.06
"Sotalol treatment led to a marked reduction in arrhythmic events."( Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Hammel, D; Haverkamp, W, 1996
)
1.35
"Sotalol treatment prolongs ventricular repolarization times (QT, p = 0.0001; JT, p = 0.0001 and JTc, p = 0.0001) in an homogeneous fashion, as showed by the significant decrease in QTc dispersion (p = 0.026) and Tp-Te interval (p = 0.011)."( [Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy].
Briglia, N; Ducceschi, V; Esposito, R; Iacono, A; Mayer, MS; Santangelo, L; Sarubbi, B; Scialdone, A, 1996
)
1.93
"Sotalol treatment was stopped and an infusion with lidocaine was started."( Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.
Bergmann, P; Kallfelz, HC; Paul, T; Sasse, M, 1998
)
2.46
"Treatment with sotalol enhanced the "zone of avoidance"."( "Zone of avoidance": RR interval distribution in tachograms, histograms, and Poincaré plots of a Boxer dog.
Gladuli, A; Hemsley, SA; Moïse, NS; Otani, NF, 2010
)
0.7
"Treatment with sotalol or mexiletine-atenolol was well tolerated and efficacious. "( Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers.
Atkins, CE; DeFrancesco, TC; Gordon, SG; Hamlin, RL; Keene, BW; Meurs, KM; Miller, MW; Moise, NS; Spier, AW; Wright, NA, 2002
)
0.67
"Treatment with sotalol and metoprolol was associated with a clinically insignificant increase in serum uric acid concentration."( Sotalol and metoprolol comparison of their anti-hypertensive effect.
Andersson, O; Berglund, G; Descamps, R; Thomis, J, 1981
)
2.05
"Treatment with sotalol exacerbated his symptoms and resulted in recurrent polymorphic ventricular tachycardia with a pattern indistinguishable from that caused by a class III action."( Sotalol associated polymorphic ventricular tachycardia and coronary spasm.
Grace, AA; Lowe, MD; Stone, DL, 1998
)
2.08
"Treatment with sotalol caused normalization or significant lowering of diastolic pressure in the majority of cases with high or normal plasma renin."( [Renin-angiotensin-aldosterone system in the treatment of essential hypertension with a beta-adrenergic blocker: sotalol].
Cuéllar, A; Psadas, C; Rangel, J; Sánchez, G; Serrano, PA; Zaldívar, HM,
)
0.68
"Treatment with Sotalol 240-320 mg/day was started and after 3.1 +/- 1.1 weeks PVS was repeated."( [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Klein, H; Lichtlen, PR; Trappe, HJ, 1987
)
0.88

Toxicity

The rhythm control agents amiodarone, flecainide and sotalol have significant adverse effects which can lead to discontinuation of their use. Sotalol was discontinued because of adverse ef.

ExcerptReferenceRelevance
" Sotalol is an effective, safe drug for the treatment of supraventricular tachycardias in early infancy."( Efficacy and safety of oral sotalol in early infancy.
Sandor, G; Tipple, M, 1991
)
1.49
" Adenosine did not terminate tachycardia or have any serious adverse effect in any patient; both flecainide and disopyramide were significantly more effective than lignocaine, but flecainide had significantly more severe adverse effects than lignocaine."( Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990
)
0.28
" A total of 15 possible adverse effects were reported, occurring in 10 patients with sotalol versus 4 with placebo."( Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group.
Gorgels, A; Jordaens, L; Stroobandt, R; Temmerman, J, 1991
)
0.78
" Drug-related adverse effects necessitating discontinuation of the drug occurred in four receiving low doses (2."( Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations.
Adan, AJ; Defauw, JA; Ernst, SM; Kingma, JH; Koomen, EM; Suttorp, MJ; Tjon Joe Gin, RM; van Hemel, NM, 1990
)
0.54
" Adverse effects forced discontinuation of therapy in 10 patients (7%): 6 secondary to symptomatic bradyarrhythmia, 2 due to refractory heart failure, 1 due to torsades de pointes, and 1 from bronchospasm."( Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
Dunnington, CS; Kehoe, RF; Mattioni, TA; Spangenberg, RB; Yu, G; Zheutlin, TA, 1990
)
0.59
" The most serious adverse event was proarrhythmia, occurring in 56 patients (4."( Clinical safety profile of sotalol in patients with arrhythmias.
Soyka, LF; Spangenberg, RB; Wirtz, C, 1990
)
0.58
"2% after intravenous d-sotalol, but no adverse symptoms developed."( Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Bigger, JT; Kidwell, GA; Reiffel, JA; Sahar, DI; Squatrito, A, 1989
)
0.86
" The observation of drug-associated serious adverse arrhythmic events emphasizes the need for individualized careful dose titration, particularly in patients with advanced organic heart disease."( Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
Blanc, JJ; Cheuvart, B; Crijns, HJ; Hohnloser, SH; Meinertz, T; Rizzon, P; Stubbs, P, 1995
)
0.59
" Sotalol was discontinued because of adverse effects in 42 (8."( Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
Dunnington, C; Ezri, MD; Kehoe, RF; Lueken, M; MacNeil, DJ; Nazari, J; Spangenberg, RB; Zheutlin, TA, 1993
)
1.49
" d-Sotalol was well tolerated and no subjective or objective adverse reactions were observed."( Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
Düren, DR; Koch, KT; van Zwieten, PA, 1995
)
1.17
" Because of adverse effects, drug therapy was discontinued in six patients."( Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias.
Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997
)
0.54
"Oral d,l-sotalol is effective and safe in patients with VT/VF."( Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
Borggrefe, M; Breithardt, G; Haverkamp, W; Hief, C; Lammers, A; Martinez-Rubio, A; Mühlenkamp, S; Wichter, T, 1997
)
1.01
" Investigators have hoped that these drugs would be as effective as sotalol and amiodarone but have fewer adverse effects."( The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
MacNeil, DJ, 1997
)
0.76
"Despite theoretical considerations, it cannot be assumed that (+)-sotalol is safe in patients with asthma."( Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma.
Aiken, TC; Bourke, SJ; Devereux, G; Fishwick, K; Hendrick, DJ, 1998
)
0.8
" There were no cardiovascular adverse events during either loading phase."( Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
Barbey, JT; Hinderling, PH; Melikian, AP; Sale, ME; Shi, J; Woosley, RL, 1999
)
0.52
" Patients had ECG monitoring for 48 hours, and time of reversion, adequacy of rate control, and numbers of adverse events were compared."( A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Joseph, AP; Ward, MR, 2000
)
0.53
" There were also fewer adverse events in the active treatment group compared with the rate control group."( A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Joseph, AP; Ward, MR, 2000
)
0.53
" Nine patients (9%) in the propafenone group, 11 (10%) in the sotalol group, and 3 (3%) in the placebo group discontinued therapy due to adverse effects."( Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001
)
0.81
" Both dofetilide and sotalol were well tolerated during the long term with no statistically significant difference in the adverse events."( A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
Biffi, M; Borggrefe, M; Boriani, G; Brachmann, J; Butrous, GS; Capucci, A; Kornacewicz-Jack, Z; Lubinski, A; Niederle, R; Wnuk-Wojnar, AM, 2001
)
0.84
"A rapid onset of an effective and safe antiarrhythmic sotalol therapy, especially for infants and neonates, is frequently delayed because of age-dependent interpatient variability in pharmacokinetics and pharmacodynamics."( Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005
)
0.81
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up."( Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007
)
0.34
" Endoluminal norepinephrine is safe in pigs and may be useful under endoscopy of the pyeloureter."( Endoluminal norepinephrine inhibits smooth muscle activity of the pig pyeloureter by stimulation of beta-adrenoceptors without side effects.
Andreasen, F; Holst, U; Jakobsen, JS; Mortensen, J, 2008
)
0.35
" Rhythm control agents are associated with clinically important adverse events."( Rhythm control agents and adverse events in patients with atrial fibrillation.
Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010
)
0.36
"The aim of this study was to assess the risk of adverse events in patients with AF receiving rhythm control agents."( Rhythm control agents and adverse events in patients with atrial fibrillation.
Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010
)
0.36
"This is a retrospective case control note review and outcome linkage analysis on the GPRD routine clinical dataset to evaluate the adverse events and predictors of treatment discontinuation in patients using licenced rhythm modifying medication."( Rhythm control agents and adverse events in patients with atrial fibrillation.
Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010
)
0.36
"The rhythm control agents amiodarone, flecainide and sotalol have significant adverse effects which can lead to discontinuation of their use."( Rhythm control agents and adverse events in patients with atrial fibrillation.
Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010
)
0.61
" The purpose of this randomized, 2-treatment, 2-period, crossover study was to develop a safe dosing regimen for intravenous sotalol that provides similar blood levels and therefore similar efficacy and safety to orally administered sotalol."( Developing a safe intravenous sotalol dosing regimen.
Molnar, J; Preston, RA; Ranade, V; Somberg, JC,
)
0.63
" High-dose sotalol allows for safe and rapid control of refractory tachyarrhythmias in this young age group."( High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias.
Cannon, BC; Kim, JJ; Knudson, JD; Moffett, BS, 2011
)
1.16
" Adverse events (AEs) associated with AADs may influence patient compliance and compromise the management of atrial fibrillation (AF)."( One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
Jhaveri, M; Kim, MH; Klingman, D; Lin, J; Smith, PJ, 2011
)
0.58
"Dronedarone could represent an effective and safe option in patients previously treated with AADs, especially class Ic AADs and sotalol."( Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014
)
0.61
" Dronedarone was equally effective irrespective of whether class Ic or sotalol were stopped for lack of efficacy or adverse events (AEs)."( Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014
)
0.64
" Risk factors for adverse events (AEs), defined as any arrhythmia or electrocardiogram change requiring dose reduction or cessation, were identified."( Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015
)
0.66
" Adverse effects, including proarrhythmia, were documented."( Efficacy and adverse effects of sotalol in adults with congenital heart disease.
Celermajer, DS; Cordina, RL; McGuire, MA; Moore, BM, 2019
)
0.8
"In moderate to highly complex adult CHD, sotalol was reasonably effective and safe in low doses."( Efficacy and adverse effects of sotalol in adults with congenital heart disease.
Celermajer, DS; Cordina, RL; McGuire, MA; Moore, BM, 2019
)
1.06
" Results obtained for SOT and RAN showed that acute adverse effects are not expected to occur on aquatic organisms at the concentrations at which these pharmaceuticals are usually found in fresh surface waters."( Assessment of the ecotoxicity of the pharmaceuticals bisoprolol, sotalol, and ranitidine using standard and behavioral endpoints.
Assano, PK; de Almeida Vergara Hidalgo, V; de Carvalho, LB; de Jesus Azevedo, CC; Domingues, I; Godoy, AA; Kummrow, F; Mori, V; Nogueira, AJA; Oliveira, ÁC; Taparo, JM, 2020
)
0.8
"The purpose of this study was to determine the frequency of adverse events (AEs) during sotalol initiation for the management of atrial, supraventricular, or ventricular arrhythmias in pediatric patients."( Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
Abrams, DJ; Alexander, ME; Bevilacqua, LM; Bezzerides, VJ; Chandler, SF; Chu, E; DeWitt, ES; Mah, DY; Triedman, JK; Walsh, EP; Whitehill, RD, 2020
)
1.06
" Efficacy and adverse events in this cohort have not been well described."( "Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide.
Kahr, PC; Kim, JJ; Miyake, CY; Moffett, BS; Valdes, SO, 2021
)
0.82
" Although predominantly safe in otherwise healthy patients, electrocardiogram changes can occur and children with underlying cardiac disease may have an increased risk of adverse events and rhythm-related side effects during initiation."( "Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide.
Kahr, PC; Kim, JJ; Miyake, CY; Moffett, BS; Valdes, SO, 2021
)
0.82
"This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC."( Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022
)
0.72
" Adverse events interrupting IV sotalol infusion included bradycardia (seven patients, 24."( Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay.
Arora, R; Charron, J; Chicos, A; Fugaro, D; Gao, X; Gay, H; Kaplan, R; Kim, S; Knight, BP; Lin, AC; Liu, AY; Lohrmann, G; Passman, R; Patil, K; Pfenniger, A; Spoolstra, S; Verma, N, 2023
)
1.48
"The DASH-AF trial shows that rapid IV sotalol loading in atrial fibrillation/flutter patients for rhythm control is feasible and safe compared with conventional oral loading with significant cost reduction."( Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF).
Ahmed, A; Atkins, D; Bawa, D; Bommana, S; Bush, J; Charate, R; Darden, D; Garg, J; Gopinathannair, R; Kabra, R; Kennedy, R; Koreber, S; Lakkireddy, D; Mohanty, S; Natale, A; Park, P; Pothineni, NVK; Seo, BW; Tummala, R; Vasamreddy, C, 2023
)
1.45

Pharmacokinetics

The effects of beta-blocking agents on the symptoms of hyperthyroidism are correlated with the serum concentration of the drugs. Sotalol, with its long half-life and unaltered elimination in hyperthy thyroidism, has certain advantages over propranolol in treatment of thyrotoxicosis.

ExcerptReferenceRelevance
" The processes of distribution and elimination are of first order; the intravenous biological half-life is 6 to 8 hours."( Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man.
Klein, G; Schinz, A; Schnelle, K,
)
0.35
"Present investigation was undertaken to elucidate what pharmacokinetic parameters in animal experiment could be of more predictable for human clinical trial of beta-blocking agents."( [Studies on the pharmacokinetics and effects of beta-adrenergic blocking agents, sotalol (author's transl)].
Tawara, K, 1977
)
0.48
" The half-life of sotalol in plasma was 12."( Observations on the efficacy and pharmacokinetics of sotalol after oral administration.
Brown, HC; Carruthers, SG; Kelly, JG; McDevitt, DG; Shanks, RG, 1976
)
0.84
" There were no significant differences between pharmacokinetic parameters of enantiomers."( Pharmacokinetics of sotalol enantiomers in humans.
Carr, RA; Foster, RT; Hamilton, PG; Lewanczuk, RZ, 1992
)
0.61
" Pharmacokinetic parameters were compared with those obtained previously in non-obese control subjects."( Comparison of propranolol and sotalol pharmacokinetics in obese subjects.
Barré, J; Cheymol, G; Cohen, A; Hugues, FC; Le Jeunne, C; Poirier, JM, 1990
)
0.57
" In obese subjects the pharmacokinetic data calculated for sotalol (total clearance (CL), volume of distribution (V beta), half-life of elimination (t1/2), were comparable with those measured in the controls."( [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
Cheymol, G, 1990
)
0.52
" Cmax of sotalol is 2 to 3 hours with a t1/2 between 7 and 15 hours."( Pharmacology, pharmacodynamics and pharmacokinetics of sotalol.
Antonaccio, MJ; Gomoll, A, 1990
)
0.94
"Comparative pharmacokinetic studies with the beta-receptor blocking drugs propranolol, metoprolol, sotalol and atenolol, differing greatly in lipophilicity, and their main route of elimination were performed in light-dark-synchronized rats after equimolar single (6 mumoles/kg) or multiple (6 X 6 mumoles/kg) drug application."( Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
Fink, M; Lemmer, B; Ohm, T; Winkler, H, 1985
)
0.7
" Combining Class II and Class III antiarrhythmic properties, sotalol can be given either intravenously or orally and its pharmacokinetic properties permit long dosing (once or twice daily) intervals."( Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Deedwania, P; Nademanee, K; Singh, BN; Sorkin, EM; Ward, A, 1987
)
1.96
" The assay procedure has been successfully used during pharmacokinetic studies in healthy volunteers and patients as well as during toxicokinetic analysis."( Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography.
Braun, J; Geldmacher-von Mallinckrodt, M; Gluth, B; Gluth, WP; Sörgel, F, 1988
)
0.61
" The data indicate that d-sotalol is equipotent with l-sotalol in lengthening the action potential duration and effective refractory period in cardiac muscle, an action unrelated to adrenergic antagonism or pharmacokinetic differences between the stereoisomers."( Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics.
Ikeda, N; Kannan, R; Kato, R; Singh, BN; Yabek, SM, 1986
)
0.81
" Plasma samples were analysed for sotalol using a fluorometric method and the pharmacokinetic profiles investigated."( Pharmacokinetics of sotalol during pregnancy.
Leahey, W; McDevitt, DG; Murnaghan, GA; O'Hare, MF, 1983
)
0.87
" As the effects of beta-blocking agents on the symptoms of hyperthyroidism are correlated with the serum concentration of the drugs, sotalol, with its long half-life and unaltered elimination in hyperthyroidism, has certain advantages over propranolol in the treatment of thyrotoxicosis."( Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
Anttila, M; Aro, A; Korhonen, T; Sundquist, H, 1982
)
0.74
" d-Sotalol has pharmacokinetic properties that resemble those of the racemate."( Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
Advani, SV; Singh, BN, 1995
)
1.15
" Following oral administration, absorption and bioavailability are almost complete; apparent elimination half-life ranges from 7 to 18 hours."( Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
Funck-Brentano, C, 1993
)
0.54
" In subjects with normal renal function, total body clearance of sotalol averages 150 mL/min and the terminal elimination half-life is 10-20 hours."( Clinical pharmacokinetics of sotalol.
Hanyok, JJ, 1993
)
0.82
" In the single dose studies, the half-life of (-)-sotalol (7."( Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers.
Ikeda, Y; Kimura, M; Kosuge, K; Mizuno, A; Nakanomyo, H; Nakashima, M; Ohashi, K; Umemura, K, 1996
)
0.8
"The pharmacokinetic data for the three drugs were qualitatively similar."( Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997
)
0.3
"The shorter serum half-life in the later phase is comparable with that in four previously reported sotalol intoxications and within the normal range."( Pharmacokinetic evaluation of a case of massive sotalol intoxication.
Gustavsson, CG; Norlander, BO; Pantev, E; Vinge, E,
)
0.6
" Pharmacokinetic and pharmacodynamic parameters were obtained with standard methods."( Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
Barbey, JT; Beerman, L; Hinderling, PH; Jin, J; Melikian, AP; Ross, B; Saul, JP; Schaffer, MS; Shi, J; Williams, J, 2001
)
0.58
"To derive useful pharmacokinetic (PK) and pharmacodynamic (PD) information for guiding the clinical use of sotalol in pediatric patients with supraventricular (SVT) or ventricular tachyarrhythmia (VT)."( Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.
Gastonguay, MR; Hinderling, PH; Ludden, TM; Melikian, AP; Shi, J, 2001
)
0.77
" The method was applied to the pharmacokinetic monitoring of sotalol (STL) in the plasma of five young healthy volunteers, dosed with racemic drug."( Enantioselective liquid chromatographic-electrospray mass spectrometric assay of beta-adrenergic blockers: application to a pharmacokinetic study of sotalol in human plasma.
Badaloni, E; D'Acquarica, I; Gasparrini, F; Lalli, S; Misiti, D; Pazzucconi, F; Sirtori, CR, 2003
)
0.76
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" The pharmacokinetic analysis revealed that sotalol concentrations from microdialysates were not different from conventional plasma samples (100+/-11%, n=33) resulting in subsequent comparable pharmacokinetic parameters."( Development of an intravenous microdialysis method for pharmacokinetic investigations in humans.
Elshoff, JP; Läer, S,
)
0.39
"This stepwise approach using an in vitro device enabled us to demonstrate the determination of pharmacokinetic parameters of sotalol."( Development of an intravenous microdialysis method for pharmacokinetic investigations in humans.
Elshoff, JP; Läer, S,
)
0.34
"The objective of this study was to develop age-specific dosage guidelines for sotalol in children with supraventricular tachycardia (SVT) based on a population pharmacokinetic covariate analysis, clinical trial simulations, and pharmacodynamics."( Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005
)
0.79
"9 mg/kg/day using population pharmacokinetic analysis and clinical trial simulation (n = 76), pharmacokinetic/pharmacodynamic modeling for QT interval prolongation (n = 32), and for the concentration-antiarrhythmic-response relationship (n = 15)."( Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005
)
0.57
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"In recent years, the increased interest in pediatric research has enforced the role of physiologically based pharmacokinetic (PBPK) models in pediatric drug development."( Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
Khalil, F; Läer, S, 2014
)
0.61
"In order to bridge the gap of action of dl-sotalol between the human ether-a-go-go-related gene (hERG) K(+) channel inhibition in vitro and QT-interval prolongation in vivo, its electropharmacological effect and pharmacokinetic property were simultaneously studied in comparison with those of 10 drugs having potential to prolong the QT interval (positive drugs: bepridil, haloperidol, dl-sotalol, terfenadine, thioridazine, moxifloxacin, pimozide, sparfloxacin, diphenhydramine, imipramine and ketoconazole) and four drugs lacking such property (negative drugs: enalapril, phenytoin, propranolol or verapamil) with the halothane-anesthetized guinea pig model."( Why Can dl-Sotalol Prolong the QT Interval In Vivo Despite Its Weak Inhibitory Effect on hERG K(+) Channels In Vitro? Electrophysiological and Pharmacokinetic Analysis with the Halothane-Anesthetized Guinea Pig Model.
Ando, K; Cao, X; Honda, A; Izumi-Nakaseko, H; Katagi, J; Nakamura, Y; Ohara, H; Sugiyama, A, 2016
)
1.09
"94 h, a moderate distribution and a mean elimination half-life of 15."( Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function.
Broux, B; Croubels, S; De Baere, S; De Clercq, D; Decloedt, A; Devreese, M; Van Der Vekens, N; van Loon, G; Ven, S, 2016
)
0.68
" The present study aimed to increase the understanding of oral drug absorption in paediatric populations by using physiologically based pharmacokinetic (PBPK) modelling and in vitro dissolution testing."( Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.
Kuentz, M; Parrott, N; Stillhart, C; Villiger, A, 2016
)
0.43
" A physiologically based pharmacokinetic model was built for sotalol, a renally eliminated drug, to simulate infant drug exposure from human milk."( Informing a Comprehensive Risk Assessment of Infant Drug Exposure From Human Milk: Application of a Physiologically Based Pharmacokinetic Lactation Model for Sotalol.
Ceresa, C; Fletcher, EP; Florian, J; Guinn, D; Liu, Z; Madabushi, R; Pressly, MA; Samuels, S; Schmidt, S, 2023
)
1.35

Compound-Compound Interactions

This study assessed the efficacy of the combination of sotalol and either quinidine or procainamide in preventing sustained ventricular tachycardia inducibility and recurrence. Using standard microelectrode techniques, the authors compared the effects of 15 to 125 microM concentrations of mexiletine, 31 to 500 microM concentrations of sotalol, on beat-to-beat maximum rate of depolarization of phase 0 of the action potential.

ExcerptReferenceRelevance
"Using standard microelectrode techniques, the authors compared the effects of 15 to 125 microM concentrations of mexiletine, 31 to 500 microM concentrations of sotalol and 15 to 125 microM of mexiletine combined with 125 microM sotalol, on the beat-to-beat maximum rate of depolarization of phase 0 of the action potential (Vmax) of porcine papillary muscles and Purkinje fibres stimulated by 30 beat trains at a frequency of 1 Hz."( The cellular electropharmacology of mexiletine combined with sotalol in porcine papillary muscle and Purkinje fibre. I. Alteration of mexiletine-induced Vmax depression.
Ahmed, A; Berman, ND; Wang, LY, 1990
)
0.72
"Using standard microelectrode techniques, the authors compared the effects of 15 to 125 microM concentrations of mexiletine, 31 to 500 microM concentrations of sotalol and 15 to 125 microM of mexiletine combined with 125 microM sotalol, on the beat-to-beat action potential duration and refractoriness of porcine papillary muscles and Purkinje fibres stimulated by 30 beat trains at a frequency of 1 Hz."( The cellular electropharmacology of mexiletine combined with sotalol in porcine papillary muscle and Purkinje fibre. II. Effects on action potential duration and refractoriness.
Ahmed, A; Berman, ND; Wang, LY, 1990
)
0.72
"Quinidine combined with propranolol produces antiarrhythmic synergism."( Comparative antiarrhythmic activity of quinidine combined with propranolol and with sotalol.
Lawson, JW; Wojciechowski, NJ, 1981
)
0.49
"This study assessed the efficacy of the combination of sotalol and either quinidine or procainamide in preventing sustained ventricular tachycardia inducibility and recurrence and prospectively evaluated the ability of the drug combination to prevent ventricular tachycardia recurrence when the arrhythmia remained inducible but was modified."( Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993
)
1.98
" Among patients in whom this drug combination was unsuccessful at electrophysiologic study (group III) and in those who received alternative therapy after combination therapy was discontinued because of side effects, actuarial recurrence rates were 9%, 14% and 32% at 1, 2 and 3 years, respectively."( Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993
)
1.73
" This drug combination deserves further evaluation."( Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993
)
1.73
" The mechanisms underlying the efficacy of this drug combination have not been fully elucidated."( Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Dorian, P; Ham, M; Lee, SD; Newman, D, 1997
)
0.54
" Class III antiarrhythmic drugs may interact with other drugs by two major processes: pharmacodynamic and pharmacokinetic interactions."( Potentially significant drug interactions of class III antiarrhythmic drugs.
DeBisschop, M; Lower, DL; Martin, LG; Yamreudeewong, W, 2003
)
0.32
" In the current paper, this new extraction technique was combined with liquid chromatography-mass spectrometry (LC-MS) for the first time."( Liquid-phase microextraction based on carrier mediated transport combined with liquid chromatography-mass spectrometry. New concept for the determination of polar drugs in a single drop of human plasma.
Anthonsen, HS; Ho, TS; Pedersen-Bjergaard, S; Rasmussen, KE; Reubsaet, JL, 2005
)
0.33
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" The electrophysiologic mechanisms of ranolazine in combination with class III drugs were studied in an isolated whole-heart model of stretch-related AF."( Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013
)
0.39

Bioavailability

An investigation on the bioavailability of a new tablet with 80 mg sotalol hydrochloride (Rentibloc mite, CAS 959-24-0) was performed in a two-way cross-over study with 16 persons. Sotalol is highly bioavailable when administered orally in the fasting state and is mostly cleared unchanged in the urine.

ExcerptReferenceRelevance
"The effect of food, some food constituents, and large volumes of fluid taken with the drug on the relative bioavailability of sotalol has been examined in five healthy volunteers."( Effect of food, food constituents and fluid volume on the bioavailability of sotalol.
Anttila, M; Kahela, P; Sundquist, H; Tikkanen, R, 1979
)
0.69
" Compound 5 was shown to have good oral bioavailability and a favorable hemodynamic profile to produce a 3-fold increase of the ventricular fibrillation threshold and to terminate ventricular fibrillation, restoring sinus rhythm in anesthetized dogs."( Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
Bagli, JF; Ellingboe, JW; Kitzen, JM; Moubarak, IF; Nguyen, TT; Parsons, RW; Spinelli, W; Von Engen, D; Winkley, MW, 1992
)
0.28
" Consequently, bioavailability is close to 100%."( Pharmacology, pharmacodynamics and pharmacokinetics of sotalol.
Antonaccio, MJ; Gomoll, A, 1990
)
0.53
" The elimination half-life after oral administration (about 10 h) and bioavailability (about 90%) were not altered significantly by pregnancy."( Pharmacokinetics of sotalol during pregnancy.
Leahey, W; McDevitt, DG; Murnaghan, GA; O'Hare, MF, 1983
)
0.59
"The elimination and bioavailability of two beta-blocking agents, propranolol and sotalol, were studied in 10 thyrotoxic patients, both before and after treatment with iodine-131."( Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
Anttila, M; Aro, A; Korhonen, T; Sundquist, H, 1982
)
0.77
"The effect of concurrent administration of antacids on the relative bioavailability of sotalol has been examined in five healthy volunteers."( Antacids and sotalol absorption.
Anttila, M; Kahela, P; Sundqvist, H, 1981
)
0.85
"An investigation on the bioavailability of a new tablet with 160 mg sotalol hydrochloride (CAS 959-24-0, Rentibloc 160), was performed in a two-way cross-over study with 16 volunteers."( [Testing of bioequivalence of a new sotalol hydrochloride preparation in comparison to a standard formulation].
Herrmann, R; Kleinbloesem, CH, 1995
)
0.8
" Given orally, bioavailability of the drug reaches 100%."( Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound".
Claudel, JP; Touboul, P, 1995
)
1.73
" Following oral administration, absorption and bioavailability are almost complete; apparent elimination half-life ranges from 7 to 18 hours."( Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
Funck-Brentano, C, 1993
)
0.54
"Bioequivalence of a New Sotalol Hydrochloride Tablet Formulation Compared with a Standard Preparation An investigation on the bioavailability of a new tablet with 80 mg sotalol hydrochloride (Rentibloc mite, CAS 959-24-0) was performed in a two-way cross-over study with 16 persons."( [Bioequivalence of a new tablet formulation of sotalol hydrochloride in comparison to a standard preparations].
Herrmann, R; Kleinbloesem, CH, 1994
)
0.85
" Amiodarone toxicity following acute overdose is rare because poor bioavailability and a large volume of distribution limit the peak serum concentration."( Class III antiarrhythmics in overdose. Presenting features and management principles.
Holt, DW; Leatham, EW; McKenna, WJ, 1993
)
0.29
" Sotalol is well absorbed after oral administration."( Sotalol: a new class III antiarrhythmic agent.
Zanetti, LA, 1993
)
2.64
" Sotalol is highly bioavailable when administered orally in the fasting state and is mostly cleared unchanged in the urine with an apparent half-life of elimination of 15 to 17 hours."( Sotalol.
Ruffy, R, 1993
)
2.64
" As a result, its absolute bioavailability is 90-100%."( Clinical pharmacokinetics of sotalol.
Hanyok, JJ, 1993
)
0.58
" The beta-adrenergic antagonist sotalol (10-4 M) reduced LL absorption rate from -1."( The regulation of lung liquid absorption by endogenous cAMP in postnatal sheep lungs perfused in situ.
Benjamin, AR; Stephens, RH; Walters, DV, 1998
)
0.58
"The individual bioavailability of enterally administered drugs is usually uncertain in case of reduced bowel length."( [Bioavailability of sotalol in short bowel syndrome].
Bach, F; Claus, T; Juckenhöfel, S; Molter, G; Silomon, M, 1999
)
0.63
" For the assessment of the individual bioavailability plasma concentrations were measured via HPLC immediately before and 2 hours after enteral application of sotalol."( [Bioavailability of sotalol in short bowel syndrome].
Bach, F; Claus, T; Juckenhöfel, S; Molter, G; Silomon, M, 1999
)
0.82
" In addition comparative investigation of in vitro dissolution properties of different Sota-saar formulations and the reference product provided satisfying justification to waive in vivo bioavailability (BA)/bioequivalence (BE) studies."( Biopharmaceutical characterization of sotalol-containing oral immediate release drug products.
Alt, A; Moessinger, J; Oeser, H; Potthast, H; Sickmüller, B, 2004
)
0.59
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Methyl ester 20 has promising oral bioavailability and pharmacokinetics and may target 5-HT4 receptors in both CNS and peripheral organs."( Acidic biphenyl derivatives: synthesis and biological activity of a new series of potent 5-HT(4) receptor antagonists.
Andressen, KW; Brudeli, B; Klaveness, J; Levy, FO; Moltzau, LR; Nilsen, NO, 2013
)
0.39
" Orally administered sotalol has a bioavailability of nearly 100%."( Sotalol.
Kpaeyeh, JA; Wharton, JM, 2016
)
2.2
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

One hundred and two patients with atrial fibrillation, 56 males and 46 females, aged 56 +/- 11, were randomized into 2 equal groups. 10 patients in the sotalol group taking a maintenance dosage of 80 mg/d showed atrial ventricular block and severe bradycardia during the follow-up of 6-2 months.

ExcerptRelevanceReference
" The dose-response curves obtained were compared with similar curves previously reported for sotalol, practolol, and atenolol with identical experimental methods."( Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
Brown, HC; Carruthers, SG; McDevitt, DG; Shanks, RG, 1977
)
0.48
" The effects of sotalol on heart rate, blood pressure, EEG, subjective quality of sleep, polygraphically determined sleep pattern, and psychophysiological parameters such as psychomotor performance, memory, perception, vigilance, and general condition were studied and were related to dosage and plasma levels."( Effects of the beta-adrenoceptor blocking agent sotalol on CNS: sleep, EEG, and psychophysiological parameters.
Bender, W; Greil, W; Rüther, E; Schnelle, K,
)
0.73
" Once daily dosage did not cause any problems of tolerance."( Comparison of once and twice daily administration of sotalol in the treatment of hypertension.
Parvinen, I; Paukkala, E, 1979
)
0.51
" Because of this 24-hour beta-adrenoceptor blocking effect, sotalol should be suitable for once-daily dosing in clinical practice."( Blunting of exercise-induced tachycardia and renin release 24 hours after a single dose of sotalol.
Bühler, FR; Kiowski, W; Küng, M; Van Brummelen, P,
)
0.59
"Thirty patients with mild to severe essential hypertension satisfactorily controlled by twice-daily sotalol therapy entered a double-blind, crossover study comparing the efficacy, tolerability, and safety of their usual twice-daily sotalol administration with the same dosage given once daily."( Thrice-daily blood pressure readings on sotalol in the treatment of hypertension: once- versus twice-daily regimen.
Parvinen, I; Paukkala, E,
)
0.62
" These differences were maintained on repeated dosing for 8 days."( Observations on some properties of a long-acting preparation of propranolol.
Leahey, WJ; Neill, JD; Shanks, RG; Varma, MP, 1979
)
0.26
" A dose-response relationship was seen."( Once daily sotalol in the treatment of hypertension.
Shaw, HL, 1977
)
0.65
" After a two dose trial (Gillam and Prichard, 1966,) demonstrated a dose dependent anti-anginal effect, a log-dose response study demonstrated a progressive reduction in angina attacks as dosage was increased (Prichard and Gillam, 1971)."( Propranolol in the treatment of angina: a review.
Prichard, BN, 1976
)
0.26
"A study was carried out in 12 previously untreated hypertensive patients to assess the efficacy of sotalol given in a once-daily dosage regimen."( Control of hypertension with single daily doses of sotalol hydrochloride.
Gabriel, R,
)
0.6
" Since beta-blockers may impair renal function, even in therapeutic concentrations, the dosage of sotalol, in particular, must be reduced in patient with kidney disease."( Serum levels and half-life of sotalol in chronic renal failure.
Anttila, M; Forsström, J; Kasanen, A; Sundquist, HK, 1975
)
0.76
"Serum drug level monitoring facilitates dosage optimization of agents with a narrow therapeutic index."( The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
Follath, F, 1992
)
0.28
"025), and resulted in decreases in % success at each of two energy levels, falling in the midrange of the dose-response curve."( Isoproterenol increases defibrillation energy requirements in dogs.
Dorian, P; Ogilvie, RI; Wang, M, 1992
)
0.28
" Log dose-response curves for action potential prolongation and for blockade of IK by compound II were similar."( Actions and mechanisms of action of novel analogues of sotalol on guinea-pig and rabbit ventricular cells.
Connors, SP; Gill, EW; Terrar, DA, 1992
)
0.53
" The drugs were also administered over a 2-week dosing interval to conscious dogs at a dose of 5 mg/kg given twice daily."( Comparability of the electrophysiologic responses and plasma and myocardial tissue concentrations of sotalol and its d stereoisomer in the dog.
Antonaccio, MJ; Bartek, MJ; Comereski, CR; Gomoll, AW; Lekich, RF, 1990
)
0.49
"9 kg and dosage 2-4 mg/kg/24 hrs given in two equal doses, 12 hourly."( Efficacy and safety of oral sotalol in early infancy.
Sandor, G; Tipple, M, 1991
)
0.58
"8 +/- 7% at the dosage of 320 mg/24 hr and by 25."( Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.
Funck-Brentano, C; Jaillon, P; Kibleur, Y; Le Coz, F; Mallet, A; Poirier, JM, 1991
)
0.61
" The nature and mechanism of the VT was proved with electrophysiologic testing (EPS), and the chronic sotalol dosage was determined by repeated EPS at 3- to 4-day intervals until the VT was no longer inducible."( Efficacy of oral sotalol in reentrant ventricular tachycardia.
Haitus, B; Jardine, R; Millar, RN; Obel, IW, 1990
)
0.83
" In a study correlating dosage and antiarrhythmic response with prolongation of rate-corrected QT (QTc) (a measure of class III action) and the degree of beta-receptor blockade (assessed by the reduction of the maximal exercise-induced heart rate), 11 of 17 patients had an antiarrhythmic response."( Concentration/response relations for the multiple antiarrhythmic actions of sotalol.
Barbey, JT; Funck-Brentano, C; Wang, T; Woosley, RL, 1990
)
0.51
"In the smooth muscle of the rat vas deferens, 10(-5) M cocaine shifted the dose-response curve to norepinephrine to the left and enhanced the maximal contractions to norepinephrine and methacholine."( Propranolol blocks cocaine-induced potentiation of the contraction in the smooth muscle of the rat vas deferens.
Gomi, Y; Inagaki, O; Kasuya, Y; Ono, K; Suzuki, N, 1990
)
0.28
" The following were the most significant effects of MDL 19205: a decrease in action potential duration in both ventricular and Purkinje tissues; a cumulative dose-dependent increase in contractile force in ventricular muscle but not in Purkinje strands; no change in aiNa in Purkinje fibers to accompany the positive inotropic effect of this agent; a shift in the dose-response relation by approximately fourfold in the presence of beta-adrenergic blockade with sotalol (10(-7) M); an enhancement of diastolic depolarization in Purkinje fibers resulting in automaticity that is accelerated by overdrive; and a potentiation of the positive inotropic effects of MDL 19205 by 8-bromo-cAMP (1 mM), indicating a potent phosphodiesterase inhibitory action of MDL 19205."( Effects of MDL 19205 (piroximone), a new cardiotonic agent, on electrophysiological, mechanical, and intracellular ionic characteristics of sheep cardiac tissues.
Wasserstrom, JA,
)
0.29
" The mean daily dosage of sotalol was 221 +/- 84 mg."( Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989
)
0.94
" Pharmacokinetics of nisoldipine was assessed and liver blood flow (ICG clearance) was measured before dosing and at the end of the infusion or during absorption."( Variability in the pharmacokinetics of nisoldipine as caused by differences in liver blood flow response.
Blauw, GJ; Breimer, DD; Danhof, M; Ooms, P; van Brummelen, P; van Harten, J, 1989
)
0.28
" Combining Class II and Class III antiarrhythmic properties, sotalol can be given either intravenously or orally and its pharmacokinetic properties permit long dosing (once or twice daily) intervals."( Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Deedwania, P; Nademanee, K; Singh, BN; Sorkin, EM; Ward, A, 1987
)
1.96
" There was the same significant reduction of the heart rate pressure product with the low and high dosage indicating that the beta-blocker effect is achieved with the lower dosage."( The effect of sotalol on exercise-induced ventricular arrhythmias.
Glogar, D; Petzl, DH; Probst, P; Schuster, E, 1988
)
0.64
" An index of action potential duration, the rate-corrected QT (QTc), was measured using serial 12-lead electrocardiograms on the third day of each dosage at presumed steady state and the degree of beta-receptor blockade was assessed by the reduction of the maximal exercise-induced heart rate."( Concentration-dependent pharmacologic properties of sotalol.
Bergstrand, RH; Duff, HJ; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Woosley, RL, 1986
)
0.52
" Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration."( Sotalol infusion in the treatment of supraventricular tachyarrhythmias.
Harte, M; Horgan, JH; Teo, KK, 1985
)
1.71
" In a further seven experiments dl-sotalol was administered using the same dosage regimen."( d-Sotalol: a new potent class III anti-arrhythmic agent.
Donaldson, R; Sutton, P; Taggart, P, 1985
)
1.27
" The effects of six beta-adrenoceptive antagonists [(+/-)-propranolol, (+)-propranolol, (+/-)-sotalol, (+/-)-practolol, (+/-)-pindolol and (+/-)-procinolol] were studied on airway resistance and heart rate in guinea-pigs and dose-response curves constructed."( Comparative study of six -adrenoceptive antagonists on airway resistance and heart rate in the guinea-pig.
Advenier, C; Boissier, JR; Giudicelli, JF, 1972
)
0.47
"No unequivocal central effects were found with either +/--propranolol (120 mg) or +/--sotalol (240 mg) in acute dosage in normal subjects."( Central and peripheral effects of propranolol and sotalol in normal human subjects.
Lader, MH; Tyrer, PJ, 1972
)
0.73
" Quinidine inhibited T3 formation, with a dose-response curve which was similar over the concentrations studied to that of DL-propranolol."( Inhibition by propranolol of 3,5,3'-triiodothyronine formation from thyroxine in isolated rat renal tubules: an effect independent of beta-adrenergic blockade.
Campbell, DG; Heyma, P; Larkins, RG, 1980
)
0.26
" beta-Adrenoceptor blocking agents were found to interact with isoproterenol in a manner consistent with a simple competitive antagonism provided that (1) the antagonist had little intrinsic stimulant action on the preparation under study, (2) the concentrations of antagonist used had no direct depressant action on the preparation, (3) precautions were taken to assure that the pattern of antagonism was not distorted by loss of agonist into tissue sinks, and (4) dose-response curves were normalized for changes in the baseline frequency or force in successive curves."( Comparative assessment of beta-adrenoceptor blocking agents as simple competitive antagonists in isolated heart muscle: similarity of inotropic and chronotropic blocking potencies against isoproterenol.
Blinks, JR; Gilmour, DP; Kaumann, AJ; McInerny, TK, 1980
)
0.26
" Log dose-response curves for increases in both heart rate (mostly beta 1), and amplitude of physiologic tremor (beta 2) were constructed for each subject in the control state and 2 hr after 10 or 40 mg propranolol, 200 mg sotalol, or placebo."( Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor.
Fish, A; Perucca, E; Pickles, H; Richens, A, 1981
)
0.79
" Thus shifts of the dose-response curves in BP and HR were observed."( A simple method to determine the ratio of cardiac to vascular beta-receptor blockade in the rat in vivo.
Kudo, Y; Sokabe, H; Zehr, JE, 1981
)
0.26
" The dose-response curves constructed with intra-arterial or intravenous isoprenaline behave similarly in the presence of both atenolol 50 mg and propranolol 40 mg."( Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.
Arnold, JM; McDevitt, DG, 1984
)
0.27
" Thus even in low dosage sotalol may be hazardous in the presence of hypokalaemia or when combined with drugs that also prolong the QT interval."( Sotalol, hypokalaemia, syncope, and torsade de pointes.
Barlow, JB; McKibbin, JK; Millar, RN; Obel, IW; Pocock, WA, 1984
)
2.01
" Cumulative dose-response curves to the beta agonists (-)-isoproterenol and (-)-soterenol were obtained after mixing each agonist with (+/-)-sotalol at fixed ratios (Q = [antagonist]/[agonist])."( On the use of a dynamic approach to the estimation of dissociation constants for reversible competitive antagonists.
Amidon, GL; Buckner, CK, 1981
)
0.46
" It is therefore concluded that the relationship between the serum chlorthalidone level and the fall in serum potassium level is in keeping with the flat dose-response curves for the thiazide and phthalimide diuretics."( The effects of two combinations of a beta-blocker and a diuretic on diuresis in normal subjects.
Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.27
" We feel that in developing countries, where the cost of therapy is important, reserpine in a dosage of less than 0,1 mg/d plus a thiazide derivative in low dosage is preferable to a beta-blocker plus a thiazide derivative in the treatment of hypertension."( Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in Black and Indian hypertensive patients.
Bhigjee, AI; Hoosen, S; Seedat, YK, 1984
)
0.54
" Very slight accumulation of sotalol and hydrochlorothiazide was observed, so it appears unnecessary to reduce the dosage in patients with a creatinine clearance of 30 ml/min or more."( Pharmacokinetics of a fixed combination of sotalol and hydrochlorothiazide in hypertensive patients with moderate renal insufficiency.
Fillastre, JP; Fourtillan, JB; Ingrand, I; Kher, A; Lefebvre, MA, 1984
)
0.82
" There was no difference between the two sotalol dosage regimens."( Comparison of once and twice daily sotalol in exercise-induced angina pectoris.
Aberg, A; Descamps, R; Thomis, JA; Ulvenstam, G; Vedin, A; Wilhelmsson, C, 1982
)
0.81
" Dosage was individually titrated (range 80 to 480 mg daily)."( Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency.
Berglund, G; Descamps, R; Thomis, JA, 1980
)
0.58
" Agents were compared over dosage ranges that produced maximal increases in QTc interval and monophasic action potential duration (MAPD)."( Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G, 1993
)
0.56
" The concentrations of all four drugs in the sample collected during life were consistent with the dosage given and in the range accepted for normal therapy."( Differences in amiodarone, digoxin, flecainide and sotalol concentrations between antemortem serum and femoral postmortem blood.
McCarthy, PT; O'Sullivan, JJ; Wren, C, 1995
)
0.54
" In nonfailing ventricular myocardium, both DL-sotalol and D-sotalol shifted the dose-response curve for isoproterenol to higher concentrations (P < ."( Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
Fraedrich, G; Hasenfuss, G; Holubarsch, C; Just, H; Pieske, B; Posival, H; Ruf, T; Schneider, R, 1995
)
0.81
" Its potential usefulness in reversing adverse effects encountered during therapeutic dosing with beta-blockers has not been well characterized."( Sotalol-induced bradycardia reversed by glucagon.
Daya, MR; Fernandes, CM, 1995
)
1.73
" If sinus rhythm could not be established at that time, electric cardioversion was performed and the drug was continued in lower dosage thereafter."( [Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation--conversion and 12-month follow-up--a randomized comparison].
Betz, P; Kalusche, D; Roskamm, H; Stockinger, J, 1994
)
1.2
" Dosage of sotalol should be adjusted to creatinine clearance."( Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
Funck-Brentano, C, 1993
)
0.93
" Amiodarone dosing consisted of 600 mg 3 times daily for 10 days."( Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia.
Bakr, O; Daoud, E; Hummel, JD; Kou, W; Man, KC; Morady, F; Niebauer, M; Strickberger, SA; Williamson, BD, 1994
)
0.58
" Changes in systemic clearance of S-STL after either racemate or enantiomer dosing were explained by corresponding changes in renal clearance."( Stereospecific evaluation of sotalol pharmacokinetics in a rat model: evidence suggesting an enantiomeric interaction.
Carr, RA; Foster, RT; Pasutto, FM, 1994
)
0.58
" Patients were evaluated with serial ambulatory ECG monitoring and exercise testing during stable digoxin dosing and then with the addition of either a placebo or dl-sotalol, 80 mg/day, or dl-sotalol, 160 mg/day."( Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group.
Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994
)
0.73
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of sotalol hydrochloride are reviewed."( Sotalol: a new class III antiarrhythmic agent.
Zanetti, LA, 1993
)
1.95
" But further programmed ventricular stimulation was uneventful after the sotalol dosage had been increased to 160 mg three times daily."( [Reproducible ventricular flutter during programming of a DDD pacemaker].
Bienstein, B; Grosse-Heitmeyer, W; Liebetrau, M; Stauff, L, 1993
)
0.52
" The clearance of sotalol is reduced and its elimination half-life is prolonged in patients with renal insufficiency; as a result, dosage adjustment is necessary."( Clinical pharmacokinetics of sotalol.
Hanyok, JJ, 1993
)
0.91
" It has been applied to the determination of (+)- and (-)-sotalol in plasma from twelve subjects dosed with racemic sotalol."( Enantioselective analysis of sotalol in plasma by reversed-phase high-performance liquid chromatography using diastereomeric derivatives.
Baker, PV; Hooper, WD, 1995
)
0.83
" Dosing on gestational day (GD) 11 was associated with right-sided oblique cleft lip and short tail, while dosing on day 13 caused digital hypoplasia and/or amputation."( Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity.
Brown-Woodman, PD; Danielsson, BR; Snow, MD; Webster, WS, 1996
)
0.54
" It is recommended that initiation of sotalol therapy or dosage increases be performed in a monitored setting."( Evolving role of sotalol in the management of ventricular tachyarrhythmias.
McGovern, BA; O'Callaghan, PA, 1996
)
0.9
" This emphasizes the need to consider both rate of administration and the dosage when evaluating the safety and efficacy of a new class III antiarrhythmic drug."( Torsades de pointes with administration of high-dose intravenous d-sotalol to a patient with congestive heart failure.
Cines, M; Gottlieb, SS; Marshall, J,
)
0.37
" Tapering off corticosteroid dosage resulted in relapse, and complete recovery was only obtained after sotalol was stopped."( Migratory pulmonary infiltrates in a patient treated with sotalol.
Faller, M; Gangi, A; Gasser, B; Mathelin, C; Pauli, G; Popin, E; Quoix, E, 1997
)
0.76
" Little justification for the use of agents or dosing in children is available."( Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
Kuhn, RJ; Luedtke, SA; McCaffrey, FM, 1997
)
0.3
" Additional well-designed, controlled trials are needed to further evaluate the comparative efficacy of antiarrhythmics in the management of WPW and AVNRT in children, as well as to evaluate dosing and toxicity in various age groups."( Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
Kuhn, RJ; Luedtke, SA; McCaffrey, FM, 1997
)
0.3
"The effect of rac-sotalol on QT interval duration was studied in 10 patients after single oral administration (160 mg) and after 6-day multiple oral dosing (80 mg two or three times daily)."( Tolerance to the repolarization effects of rac-sotalol during long-term treatment.
Al Bunni, M; Ferrari, M; Gusella, M; Magnolfi, G; Maiolino, P; Padrini, R; Piovan, D; Zordan, R, 1997
)
0.89
" Larger well-designed studies are required to evaluate its efficacy and optimum dosage for this indication."( Is oral sotalol effective in converting atrial fibrillation to sinus rhythm?
Ferreira, E; Gin, K; Sunderji, R,
)
0.57
" Two schedules of dosing were tested: 3 x 80 mg and 2 x 160 mg during 28 days of therapy."( [Evaluation of antiarrhythmic efficacy of sotalol in various doses in patients with ventricular tachyarrhythmias].
Dabrowski, R; Gasior, Z; Jasek, S; Kowalik, I; Luczak, D; Matar, A; Skrabucha, B; Stanke, A; Szwed, H, 1997
)
0.56
" After the initial loading phase, the drug dose was tapered to maintenance levels over 7 to 12 days; thereafter, therapy was generally maintained at a dosage of 200 mg/day."( Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998
)
0.6
" The dose-response curve of prolongation of ventricular effective refractory period produced by MS-551 was shifted significantly to the left compared with that induced by sotalol."( Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
Cui, G; Sakaguchi, Y; Sen, L; Singh, BN, 1998
)
0.72
" After ICD implantation, 70 patients were randomly assigned to treatment with either metoprolol (mean dosage 104+/-37 mg/day in 35 patients) or d,l-sotalol (mean dosage 242+/-109 mg/day in 35 patients)."( Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator.
Hauer, B; Schwick, NG; Seidl, K; Senges, J; Zahn, R, 1998
)
0.79
" At each dosing extreme, on-drug JTc was significantly longer in women (p < or =0."( JTc prolongation with d,l-sotalol in women versus men.
Archibald, D; Hardy, S; Lehmann, MH; MacNeil, DJ, 1999
)
0.6
"Thirty patients with VT/VF (age: 57+/-11 years, 20 patients with coronary heart disease, 7 patients with no structural heart disease, 3 with others) and reproducible induction of VT/VF (28 patients VT, two patients VF) in a baseline PVS, were suppressible with sotalol (mean dosage 395+/-137 mg) in a subsequent PVS."( Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999
)
0.72
"The accelerated titration regimen for sotalol can shorten the time to attain the dosage usually required to effectively control arrhythmias, without excessive QT prolongation and the associated increased risk of torsades de pointes."( Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
Barbey, JT; Hinderling, PH; Melikian, AP; Sale, ME; Shi, J; Woosley, RL, 1999
)
0.79
"Currently d,l-sotalol is widely used to prevent recurrence of atrial fibrillation and/or atrial flutter, although a randomized dose-response study has not previously been conducted to guide therapy for this indication."( Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
Benditt, DG; Browne, K; Chang-Sing, P; Deering, TF; Jin, J; Singh, BN; Williams, JH; Zucker, R, 1999
)
0.93
" The mortality rate in this study was 19% (4 of 21 fetuses; 3 had SVT and 1 had AF); 3 deaths occurred just days after the initiation of sotalol therapy, and 1 occurred after a dosage increase."( Sotalol in the treatment of fetal dysrhythmias.
Kapusta, L; Kleinman, CS; Meijboom, EJ; Michon, MM; Oudijk, MA; Stoutenbeek, P; Visser, GH, 2000
)
1.95
" Dosing on Day 8, 9, or 10 resulted in a slightly higher incidence of embryonic death compared to historical controls."( Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol.
Danielsson, BR; Sköld, AC, 2001
)
0.54
" The dosing interval was 8 hours."( Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
Barbey, JT; Beerman, L; Hinderling, PH; Jin, J; Melikian, AP; Ross, B; Saul, JP; Schaffer, MS; Shi, J; Williams, J, 2001
)
0.58
" This patient was managed with a reduction in the dosage and with a regimen of digoxin and furosemide."( [Effect of sotalol on systemic hemodynamics and electrophysiology in patients with life-threatening ventricular tachyarrhythmias].
Fu, G; Shan, J; Wille, B, 1999
)
0.69
"5 mg/kg, and the U wave became greater with increased dosage of intravenous Sotalol (2 mg/kg)."( Relationship between the U wave on electrocardiogram and the midmyocardium of the left ventricular wall.
Li, Y; Lu, Z; Wang, C; Wu, J; Zhang, C, 2002
)
0.54
" However, it is commercially unavailable in a liquid dosage form."( Stability of sotalol in two liquid formulations at two temperatures.
Morosco, RS; Nahata, MC, 2003
)
0.69
"Sotalol hydrochloride can be prepared in either of 2 liquid dosage forms and stored in plastic bottles for 13 weeks at 4 or 25 degrees C without substantial loss of potency."( Stability of sotalol in two liquid formulations at two temperatures.
Morosco, RS; Nahata, MC, 2003
)
2.13
" The method was applied to the pharmacokinetic monitoring of sotalol (STL) in the plasma of five young healthy volunteers, dosed with racemic drug."( Enantioselective liquid chromatographic-electrospray mass spectrometric assay of beta-adrenergic blockers: application to a pharmacokinetic study of sotalol in human plasma.
Badaloni, E; D'Acquarica, I; Gasparrini, F; Lalli, S; Misiti, D; Pazzucconi, F; Sirtori, CR, 2003
)
0.76
"Intravenous dosing was initially done via jugular cannula."( Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation.
Banga, AK; Betageri, GV; Chaturvedula, A; Conjeevaram, R; Sunkara, G, 2003
)
0.32
"To determine how well dofetilide and Betapace AF (sotalol, approved solely for atrial fibrillation and atrial flutter), with their detailed dosing and monitoring guidelines for safety, were accepted into clinical practice during the 2 calendar years after their introduction."( New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
Kramer, JM; LaPointe, NM; Pamer, CA, 2003
)
0.57
" market suggests that drugs without a risk-management program or detailed dosing guidelines were more likely than dofetilide or Betapace AF to be selected for treatment of atrial fibrillation and atrial flutter."( New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
Kramer, JM; LaPointe, NM; Pamer, CA, 2003
)
0.32
"Dose-dependent torsades de pointes has been shown to occur with dofetilide (Tikosyn) and sotalol HCl (Betapace AF); thus, detailed dosing and monitoring recommendations to minimize this risk are included in the product labeling for both drugs."( Evaluation of the dofetilide risk-management program.
Allen LaPointe, NM; Califf, RM; Chen, A; DeLong, E; Hammill, B; Kramer, JM, 2003
)
0.54
"Better adherence to several dosing and monitoring recommendations in the dofetilide group may be caused by the presence of the risk-management program."( Evaluation of the dofetilide risk-management program.
Allen LaPointe, NM; Califf, RM; Chen, A; DeLong, E; Hammill, B; Kramer, JM, 2003
)
0.32
" Preprinted order forms or procedural guidelines, as well as computer-assisted dosing programs, can be utilized to prevent inappropriate or miscalculated dosing of these agents, which potentially can cause life-threatening ventricular arrhythmias."( Initiation and monitoring of class III antiarrhythmic agents.
Freeland, S; Worthy, C; Zolnierz, M, 2003
)
0.32
"The objective of this study was to develop age-specific dosage guidelines for sotalol in children with supraventricular tachycardia (SVT) based on a population pharmacokinetic covariate analysis, clinical trial simulations, and pharmacodynamics."( Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005
)
0.79
" Dosing recommendations derived for different age groups based on these findings were starting dose and target dose of 2 and 4 mg/kg/day for neonates, 3 and 6 mg/kg/day for infants and children <6 years, and 2 and 4 mg/kg/day for children >6 years."( Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005
)
0.57
"This study provides an example for rational drug dosage in children that copes with interpatient variability and can be easily switched to an individually guided therapy based on effective sotalol trough levels."( Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005
)
0.76
"One hundred and two patients with atrial fibrillation, 56 males and 46 females, aged 56 +/- 11, were randomized into 2 equal groups: amiodarone group, taking amiodarone 600 mg/d for 7 days, 400 mg/d for 7 days, 200 mg/d for 7 days, and then 200 mg/d as maintenance dosage if conversion to sinus rhythm occurred; and sotalol group, taking sotalol 40-80 mg/d for one week, 160 mg/d for 2 weeks and then 40-80 mg/d as maintenance dosage if conversion to sinus rhythm occurred."( [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study].
Chen, YX; Guo, WL; Huang, CX; Jiang, H; Jin, CR; Liu, ZM; Niu, F; Yang, B, 2006
)
0.8
" (4) 10 patients in the sotalol group taking a maintenance dosage of 80 mg/d showed atrial ventricular block and severe bradycardia during the follow-up of 6-2 months, then the medication was stopped, but there was no severe arrhythmia in amiodarone group."( [Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study].
Chen, YX; Guo, WL; Huang, CX; Jiang, H; Jin, CR; Liu, ZM; Niu, F; Yang, B, 2006
)
0.93
" A 12-lead electrocardiogram (ECG) was obtained at baseline, 3 hours, and 51 hours after dosing to correspond to the Tmax after oral ingestion."( An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
Coleman, CI; Guertin, D; Henyan, NN; Kluger, J; McBride, BF; Min, B; Silver, BB; White, CM, 2006
)
0.55
"Beta-adrenoceptor blocking drugs (beta-blockers) are one of the most frequently used class of cardiovascular drugs that are mainly used in conventional dosage forms."( Transdermal delivery of beta-blockers.
Ali, A; Aqil, M; Sultana, Y, 2006
)
0.33
" The method has been applied to the determination of sotalol in plasma from 12 subjects dosed with racemic sotalol."( Development an ion-pair liquid chromatographic method for determination of sotalol in plasma using a monolithic column.
Foroutan, SM; Khoddam, A; Shafaati, A; Zarghi, A, 2006
)
0.81
"The current recommended starting dose of sotalol is 80 mg orally twice per day, followed by a judicious increase in dosage every 3 days under continuous telemetry monitoring."( Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias.
Gerling, BR; Greenberg, ML; Holzberger, PT; Jones, DR; Juriansz, GJ; Kim, RJ, 2006
)
0.84
" Such an accelerated dosing regimen neither shortened hospitalization nor had any effect on treatment efficacy in this retrospective analysis."( Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias.
Gerling, BR; Greenberg, ML; Holzberger, PT; Jones, DR; Juriansz, GJ; Kim, RJ, 2006
)
0.57
" However, no information appears in the literature, except in abstract form, regarding the dose-response effects of sotalol in unanesthetized monkeys."( Dose-response effects of sotalol on cardiovascular function in conscious, freely moving cynomolgus monkeys.
Cox, BF; Hernandez, LE; Lynch, JJ; Marsh, KC; Mittelstadt, SW; Nelson, RA; Wilson, AW, 2008
)
0.86
"QT interval was significantly prolonged starting 1 hour 20 minutes after drug dosing with 160 mg and 1 hour 10 minutes after drug dosing with 320 mg."( The time course of new T-wave ECG descriptors following single- and double-dose administration of sotalol in healthy subjects.
Badilini, F; Dreyfus, G; Dubois, R; Extramiana, F; Leenhardt, A; Maison-Blanche, P; Roussel, P; Vaglio, M, 2010
)
0.58
" The purpose of this randomized, 2-treatment, 2-period, crossover study was to develop a safe dosing regimen for intravenous sotalol that provides similar blood levels and therefore similar efficacy and safety to orally administered sotalol."( Developing a safe intravenous sotalol dosing regimen.
Molnar, J; Preston, RA; Ranade, V; Somberg, JC,
)
0.63
" Age-factor nomogram dosing of sotalol is widely used; however, our institution uses greater doses based on body surface area (approximately 150-200 mg/m(2)/d)."( High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias.
Cannon, BC; Kim, JJ; Knudson, JD; Moffett, BS, 2011
)
1.06
" To reduce potential life-threatening ADEs, medication safety initiatives that ensure appropriate dosing of sotalol are necessary."( Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
Finks, SW; Manguso, AH; Rogers, KC, 2011
)
0.94
" Thirty-two (89%) were dosed inappropriately with respect to renal function."( Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
Finks, SW; Manguso, AH; Rogers, KC, 2011
)
0.73
" Dosage adjustment or avoidance in patients with renal insufficiency, heart failure and other relative contraindications is often necessary to avoid toxicity."( Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
Finks, SW; Manguso, AH; Rogers, KC, 2011
)
0.73
" In one patient, severe hypoglycemia limited dosing to 500 mg daily, but this was sufficient for VT control."( Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011
)
0.37
" In the PAMPA studies, drug solutions at different pH's were dosed in each well and incubated for 5 h."( Sotalol permeability in cultured-cell, rat intestine, and PAMPA system.
Benet, LZ; Liu, W; Okochi, H; Zhai, SD, 2012
)
1.82
" Furthermore, our results indicate a hormetic dose-response relationship, because no effects were observed at the highest test-concentration (6."( Sublethal effects of the beta-blocker sotalol at environmentally relevant concentrations on the New Zealand mudsnail Potamopyrgus antipodarum.
Feiner, M; Geist, J; Laforsch, C; Letzel, T, 2014
)
0.67
" The issue of drug abuse becomes increasingly prominent when the dosage forms can be readily manipulated to release a high amount of opioid or to extract the drug in certain products or solvents."( Risk based in vitro performance assessment of extended release abuse deterrent formulations.
Al-Ghabeish, M; Calderon, SN; Gupta, A; Khan, MA; Xu, X, 2016
)
0.43
" It involves formulating opioids into dosage forms that will be difficult to abuse/misuse."( Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations.
Ashraf, M; Khan, MA; Korang-Yeboah, M; Rahman, Z; Siddiqui, A; Xu, X; Yang, Y, 2016
)
0.43
" There is a near linear relationship between sotalol dosage and QT interval prolongation."( Sotalol.
Kpaeyeh, JA; Wharton, JM, 2016
)
2.14
" Also, the safety of intravenous bolus dosing of 100mg over 1 and 5minutes has previously been demonstrated."( The Use of Intravenous Sotalol in Cardiac Arrhythmias.
Kovoor, P; Lakkireddy, DJ; Samanta, R; Thiagalingam, A; Turner, C, 2018
)
0.79
" QTc prolongation was observed in the marmosets dosed with sotalol, astemizole, flecainide, quinidine, verapamil and terfenadine."( Telemetered common marmosets is useful for the assessment of electrocardiogram parameters changes induced by multiple cardiac ion channel inhibitors.
Hinoi, E; Miyawaki, I; Tsubouchi, T; Watanabe, K; Yamada, T, 2019
)
0.76
" Due to its QT-prolonging effect and subsequent increased risk of torsade de pointes, many centers admit patients during the initial dosing period."( Multicenter Analysis of Dosing Protocols for Sotalol Initiation.
Biswas, M; Chung, M; Levy, A; Newton-Cheh, C; Noseworthy, PA; Rosenberg, MA; Tarakji, K; Weber, R, 2020
)
0.82
" The objective of this study was to describe prescribing practices of sotalol and dofetilide and to compare safety outcomes between standard and nonstandard dosing strategies."( Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Knowles, D; Malloy, R; Ting, C, 2020
)
1.15
" Nonstandard dosing was associated with a greater incidence of QTc prolongation compared to standard dosing (57."( Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Knowles, D; Malloy, R; Ting, C, 2020
)
0.92
" A medication episode was defined as a timeframe in which the highest dosage at a fixed level of a single drug was used in a patient."( The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study.
Bertels, RA; Blom, NA; Filippini, LH; Kammeraad, JAE; Knobbe, I; Kuipers, IM; Zeelenberg, AM, 2021
)
0.62
" Patient and dosing characteristics were described descriptively and the impact of dosing schedule was correlated with daily hospital costs/clinical outcomes during the index hospitalization and for 30 days."( Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation.
B Muhlestein, J; Burnham, TS; Jared Bunch, T; L Anderson, J; L Bair, T; Steinberg, BA; T May, H; U Knowlton, K; Varela, DL, 2022
)
1.02
"In-patient oral sotalol dosing is markedly variable and results in the potential of both cost gain and loss to a hospital."( Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation.
B Muhlestein, J; Burnham, TS; Jared Bunch, T; L Anderson, J; L Bair, T; Steinberg, BA; T May, H; U Knowlton, K; Varela, DL, 2022
)
1.37
" A multicenter registry study was designed to evaluate the safety, efficacy, and dosing of IV sotalol."( IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study.
Asaki, SY; Avari Silva, JN; Balaji, S; Chang, PM; Fischbach, PS; Garnreiter, JM; Kirk, C; Malloy-Walton, LE; Moak, JP; Nguyen, HH; Ochoa, LA; Patel, AR; Saul, JP; Sherman, AK; Von Bergen, NH, 2022
)
1.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
ethanolamines
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Sotalol Action Pathway478

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624146
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID743040
regulator of G-protein signaling 4Homo sapiens (human)Potency0.08440.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency19.09320.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
arylsulfatase AHomo sapiens (human)Potency5.35821.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.75190.035520.977089.1251AID504332
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency4.46680.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency12.43620.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.00350.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)193.30000.00032.63119.0000AID1207772
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)3.81690.00020.93267.2000AID41153; AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.29830.00000.66359.5499AID625205
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)7.10870.00021.46819.0000AID41153; AID42027; AID42030; AID42031; AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.83350.00011.33919.9840AID625204
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)7.20000.00233.24158.0600AID41153
Beta-2 adrenergic receptorCanis lupus familiaris (dog)IC50 (µMol)5.06670.00012.45965.2000AID40701; AID40702; AID40703
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)193.30000.00032.59559.0000AID1207772
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)193.30000.00032.63119.0000AID1207772
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)608.15000.00032.25459.6000AID1207703; AID1207772
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Kd3.58400.00000.62888.9130AID1798580
Beta-1 adrenergic receptorHomo sapiens (human)Kd3.58400.00010.803910.0000AID1798580
Beta-3 adrenergic receptorHomo sapiens (human)Kd3.58400.00010.76318.9130AID1798580
Beta-2 adrenergic receptor Bos taurus (cattle)Kd0.58000.00061.47759.1200AID40694
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km195.90002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (133)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorCanis lupus familiaris (dog)
regulation of smooth muscle contractionBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorCanis lupus familiaris (dog)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorCanis lupus familiaris (dog)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of lipophagyBeta-2 adrenergic receptorCanis lupus familiaris (dog)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorCanis lupus familiaris (dog)
protein homodimerization activityBeta-2 adrenergic receptorCanis lupus familiaris (dog)
norepinephrine bindingBeta-2 adrenergic receptorCanis lupus familiaris (dog)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
early endosomeBeta-2 adrenergic receptorCanis lupus familiaris (dog)
Golgi apparatusBeta-2 adrenergic receptorCanis lupus familiaris (dog)
receptor complexBeta-2 adrenergic receptorCanis lupus familiaris (dog)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (327)

Assay IDTitleYearJournalArticle
AID72554Peak isometric tension during the basic stimulus trains (S1) during control and compound induced tension, expressed as percent control.2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID60493Efficacy in blocking sustained ventricular tachycardia (rate>250 bpm) elicited by programmed electrical stimulation in conscious dogs after iv administration of dose 3 mg/kg; no. of successful exp / total no. of exp = 4/41987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID60250Number of active animals / number of tested animals in programmed electrical stimulation model (PES)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID71923Dose required to produce 20% increase in effective refractory period in male ferret.2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines.
AID60319Percent change in Effective refractory period after intravenous administration of 3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1668034Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1810681Agonist activity at in human TLX LBD expressed in human HEK293T cells coexpressing Gal4-VP 16 assessed as increase in reporter activity measured after 14 hrs by luciferase reporter gene assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID59250Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID61707In vivo isoproterenol response in conscious dogs at 0.3 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID41488Selectivity for beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID218875In vitro activity in isolated canine cardiac ventricular muscle tissue given as 20 percent increase or decrease in FRP (functional refractory period)1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID47945Beta-adrenoceptor blocking potency in cat as dose causing 50% inhibition of the tachycardia produced by 0.2 ug/kg iv of isoproterenol1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID62968Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID60101In vivo PES efficacy in 9 conscious dogs (PES programmed electrical stimulation protocol)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1810695Inhibition of cell migration in human T98G cells at 75 uM incubated for 24 hrs by crystal violet staining based by Boyden chamber method2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID58649In vivo heart rate in anesthetized dog at 30 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID59264Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID56693Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV, at a concentration of 0.3 uM1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID56687Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 300 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56531Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID233479Ratio of number of active animals to number of treated at dose 0.3 mg/kg administered intraperitoneally in Epinephrine-induced model in anesthetized dogs; 6/61990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID59256Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID56698Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV, at a concentration of 0.3 uM1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID176310Beta-adrenoceptor blocking potency was estimated in vivo by blockade of the isoproterenol tachycardia response in rat; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID62940Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID56837The percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 1.0 ug/mL1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents.
AID56678repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 300 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59402The compound was evaluated for the mean effective dose for antiarrhythmic efficacy in PES model1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID1810694Antiproliferation activity against human T98G cells measured after 72 hrs by crystal violet staining based assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID77823The maximum percent change in the maximum rate rise of the action Potential in Guinea pig right ventricular papillary muscles at concentration 1-100 uM; NS=Not significant1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID58533Percent change in rate of left ventricular pressure after intravenous administration of 0.3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID62970Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID60106In vivo efficacy against halothane/epinephrine induced arrhythmias in 6 anesthetized dogs at 3 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID414885Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as resting membrane potential at 20 um at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID56509Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1135151Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 5 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID58012The compound was evaluated the change in blood pressure at 10 mg/kg active dose1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60460In vivo coronary flow in anesthetized dog at 30 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID229873Ratio of number of active animals to number of treated at dose 0.3-10 mg/kg administered intraperitoneally in PES model in anesthetized dogs; 7/91990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID60359Efficacy in blocking sustained ventricular tachycardia (rate>250 bpm) elicited by programmed electrical stimulation in anesthetized dogs after iv administration of dose 1 mg/kg; no. of successful exp / total no. of exp = 2/71987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID58807The compound was evaluated the change in heart rate at 10 mg/kg active dose1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID78122In vivo index of cardiac contractility using paced guinea pig model1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1810693Induction of apoptosis in human T98G cells assessed as viable cells at 100 nM measured after 72 hrs by propidium iodide staining based flow cytometry2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID62939Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID59099Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID220494In vitro activity in isolated canine cardiac Purkinje fibers given as maximum change in APD95 from control value at 100 uM of concentration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID58467Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72563In vitro contractile function in isolated ferret papillary muscle at 10 uM1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID218878In vitro electrophysiological activity in isolated canine cardiac ventricular muscle tissue given as maximum change in FRP from control value at 100 uM concentration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID1668041Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID59100Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID59026In vivo mean arterial pressure in anesthetized dog at 30 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID62969Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID62369Compound was evaluated for Total peripheral resistance in dog1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID58323Compound was evaluated for change in Heart rate in dog1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID1668032Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition at 100 uM incubated for 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID58536In vivo left ventricular contractility change in anesthetized dog at 30 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID60918Percent change in QTc interval after intravenous administration of 0.3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID63480Percent change in FRP from control at active dose 10-30 mg/kg administered intraperitoneally in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID63502Concentration that causes a 20% increase in APD95 (action potential duration at 95% repolarization) from control value in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID56510Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1135150Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 3 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID59245Effect on atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID59270Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID63506Concentration at which maximum change in APA95 was observed from control value in anesthetized dogs; The maximum observed change APD95 from control value and concentration at 100 uM when this occurred1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID218752Percent change in heart rate (HR) from control at active dose 0.3-10 mg/kg administered intraperitoneally in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID59023Compound was evaluated for Mean arterial pressure in dog1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID58009The compound was evaluated for the change in blood pressure at MED for 0.1-30 dose range in PES model1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID40701Binding affinity towards Beta-2 adrenergic receptor by displacing [3H]dihydroalprenolol, in partially purified membrane fractions from canine lung tissue in the presence of 0.1 uM metoprolol1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID22627Maximum rate of depolarization of the upstroke of the action potential1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID48984Percent change in force of contraction from control at a 10 uM concentration of compound (contractile function)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID56099Compound was evaluated for Cardiac output in dog1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID161144Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID59389In vivo PES efficacy in conscious dogs (iv)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID392048Cardiotoxicity in iv dosed Dunkin-Hartley guinea pig assessed as drug level required to evoke 50 ms QTc prolongation administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
AID1207703Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID215614Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly beta-adrenoceptors was determined.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Correlation between affinity toward adrenergic receptors and approximate electrostatic potentials of phenylethylamine derivatives. 1. Effects of the side chain.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID218750Percent change in blood pressure (BP) from control at active dose 0.3-10 mg/kg administered intraperitoneally in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID63423Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 30 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID55773Concentration required for 20% increase in the functional refractory period of canine ventricular muscle (extracellular electrophysiology) in vitro was reported. Range is between 9-40001987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID74038Effective dose in vivo for cardiac refractoriness (ERP) using paced guinea pig model1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID56838Percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 10.0 ug/mL1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents.
AID58534Percent change in rate of left ventricular pressure after intravenous administration of 1 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID40537Selectivity for beta-1 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID75643Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 50000 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
The synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID62098Percent change in Mean Blood pressure after intravenous administration of 3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID42027Binding affinity for Beta-1 adrenergic receptor by displacing [3H]dihydroalprenolol, in partially purified membrane fractions from canine ventricular muscle in the presence of 1 uM zinterol1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID58684The compound was evaluated for the change in heart rate at MED for 0.1-30 dose range in PES model1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1668035Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID781009Apparent permeability of the compound in human Caco2 cells at 1 uM2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Acidic biphenyl derivatives: synthesis and biological activity of a new series of potent 5-HT(4) receptor antagonists.
AID414888Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential duration measured at 90% repolarization at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID60317Percent change in Effective refractory period after intravenous administration of 0.3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID218636Percent change in FRP from control at active dose 0.3-10 mg/kg administered intraperitoneally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID76509Maximum percent increase in 90% repolarization at a concentration of 100 uM in Guinea pig right ventricular papillary muscles1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID230079Ratio of number of active animals to number of treated at dose 10-30 mg/kg administered intraperitoneally in anesthetized dogs; No of animals tested=71990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID58817Percent change in Heart rate after intravenous administration of 3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID41890Tested for intrinsic sympathomimetic activity (ISA); Pure antagonist1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID60919Percent change in QTc interval after intravenous administration of 1 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID63421Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 300 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID42031Tested for Beta-1 adrenergic receptor selectivity in canine cardiac tissue in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID41153Tested for Beta adrenergic receptor binding inhibition from canine ventricular tissue, using [3H]dihydroalprenolol as the radioligand in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID40702In vitro Beta-2 adrenergic receptor affinity in partially purified membrane fractions from canine lung tissue using [SH]dihydroalprenolol (4.5 nM)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID59251Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID58466Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID75205The degree of cardiac depression produced by a concentration of 10 E-4 M was determined in guinea pig1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID63484Percent change in heart rate (HR) from control at active dose 10-30 mg/kg administered intraperitoneally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID62938Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID63482Percent change in blood pressure (BP) from control at active dose 10-30 mg/kg administered intraperitoneally in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID56508Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID63424Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 30 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID40703Tested for Beta-2 adrenergic receptor selectivity in canine lung tissue in anesthetized dogs1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID55901In vitro electrophysiological activity in isolated canine cardiac Purkinje fibers using standard microelectrode technique1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID233480Ratio of number of active animals to number of treated at dose 1.0 mg/kg administered intraperitoneally in Epinephrine-induced model in anesthetized dogs; 4/41990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.
AID61710In vivo isoproterenol response in conscious dogs at 3.0 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID414887Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential duration measured at 50% repolarization at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID55754Concentration required for 20% increase in action potential duration of canine Purkinje fiber (intracellular electrophysiology) in vitro measured at 95% repolarization was reported. Range is between 9-631987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.
AID56679repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 30 uM at 1000 ms (simulating normal heart rate)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID58816Percent change in Heart rate after intravenous administration of 1 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID205279Percentage inhibition of specific binding of [3H]batrachotoxin [3H]BTX) in sodium channel from cardiac myocytes at 10 uM1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID56688Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 30 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID48982Concentration necessary to prolong APD at 95% repolarization by 20% from control.1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID58468Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID75197Concentration (1-100 uM) that causes 10% prolongation in the action potential duration at 90% polarization in Guinea pig right ventricular papillary muscles1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID56530Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID1810686Agonist activity at TAE expressed in human HEK293T cells coexpressing human full-length TLX/Gal4-VP 16 assessed as renilla luciferase reporter activity incubated for 14 hrs by Dual-glo luciferase2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID74044Concentration required to prolong the effective refractory period (ERP) by 25% in isolated guinea pig left atria1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.
AID1207772Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID62370In vivo total peripheral resistance in anesthetized dog at 30 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1810692Cytotoxicity against human T98G cells assessed as cell viability by WST-1 assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID58535Percent change in rate of left ventricular pressure after intravenous administration of 3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID59244Effect on atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID48538Percentage inhibition of depressor response in cat was determined1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID60104In vivo efficacy against halothane/epinephrine induced arrhythmias in 4 anesthetized dogs at 1 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID75633Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 10000 nM1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
The synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.
AID59220Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID56532Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID58815Percent change in Heart rate after intravenous administration of 0.3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID1668033Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID62096Percent change in Mean Blood pressure after intravenous administration of 0.3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID61708In vivo isoproterenol response in conscious dogs at 1.0 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID220496In vitro activity in isolated canine cardiac Purkinje fibers given as 20 percent increase or decrease in action potential duration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID1135149Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 1 hr (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID63422Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 300 uM at 300 ms (simulating tachycardia)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID59271Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1135145Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions by force displacement transducer1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Synthesis and adrenergic beta-blocking activity of some 1,3-benzodioxole derivatives.
AID1668042Antiproliferative activity against human A375 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID56839The percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 3.0 ug/mL1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and pharmacological studies of N-substituted 6-[(2-aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, novel class III antiarrhythmic agents.
AID58528Peak range of change in left ventricular pressure in dog1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID60318Percent change in Effective refractory period after intravenous administration of 1 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID55919In vivo cardiac output in anesthetized dog at 30 mg/kg1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID59257Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID56695Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID59221Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID414890Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as maximal rate of depolarization at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID59265Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID60920Percent change in QTc interval after intravenous administration of 3 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID239780Percentage plasma protein binding towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID414886Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential amplitude at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID56689Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Class III antiarrhythmic activity of novel substituted 4-[(methylsulfonyl)amino]benzamides and sulfonamides.
AID392049Cardiotoxicity in Dunkin-Hartley guinea pig assessed as maximal QTc prolongation time at 10 mg/kg, iv administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
AID42030In vitro Beta-1 adrenergic receptor affinity in partially purified membrane fractions from canine cardiac tissue using [SH]dihydroalprenolol (4.5 nM)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.
AID60841The compound was evaluated the change in functional refractory period at 10 mg/kg active dose1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID62097Percent change in Mean Blood pressure after intravenous administration of 1 mg/kg in Anesthetized Dogs1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
4'-[(4-Piperidyl)carbonyl]methanesulfonanilides as potent, selective, bioavailable class III antiarrhythmic agents.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID59222Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID60254number of effected animals / number of tested animals at 3 mg/kg in a halothane / epinephrine model1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,029)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990656 (32.33)18.7374
1990's628 (30.95)18.2507
2000's420 (20.70)29.6817
2010's240 (11.83)24.3611
2020's85 (4.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 97.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index97.44 (24.57)
Research Supply Index7.84 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index180.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (97.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials346 (15.76%)5.53%
Reviews220 (10.02%)6.00%
Case Studies203 (9.24%)4.05%
Observational8 (0.36%)0.25%
Other1,419 (64.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (44)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation [NCT06096337]387 participants (Anticipated)Interventional2023-12-15Not yet recruiting
Genetics of QT Prolongation With Antiarrhythmics [NCT02439658]1,000 participants (Anticipated)Observational2014-01-31Recruiting
Open-label, Randomized, Crossover, Two-period, Two-sequence Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex®, Tablets, 160 mg (BRISTOL-MYERS SQUIBB GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting [NCT03799536]Phase 136 participants (Actual)Interventional2019-01-09Completed
Randomized Controlled Phase IV Multicentric Trial, Comparing the Efficacy and Safety of Radiofrequency Substrate Ablation of Monomorphic Ventricular Tachycardia vs. Antiarrhyhtmic Drugs in Patients Experiencing Appropriate ICD Shocks [NCT03734562]180 participants (Actual)Interventional2010-07-31Completed
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04767061]Phase 49 participants (Actual)Interventional2021-04-01Completed
Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation (DASH-AF) [NCT04473807]Phase 480 participants (Anticipated)Interventional2021-01-02Recruiting
Identification of the Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation at a Pharmacological and Physiological Stimulus in an Apparently Normal Population [NCT00773201]Phase 1997 participants (Actual)Interventional2008-02-29Completed
Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial [NCT02114528]Phase 440 participants (Anticipated)Interventional2014-10-31Terminated(stopped due to Low recruitment. Pilot trial.)
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up. [NCT02294955]152 participants (Actual)Interventional2008-05-31Active, not recruiting
A Randomized, Controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation. [NCT00523978]Phase 3245 participants (Actual)Interventional2006-10-31Completed
Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation [NCT02145546]Phase 4600 participants (Anticipated)Interventional2014-05-31Not yet recruiting
Acute Management of Paroxysmal Atrial Fibrillation With Beta Blockers Plus Intravenous Flecainide: a Real-world Chios Registry (BETAFLEC-CHIOS) [NCT04991896]81 participants (Actual)Observational [Patient Registry]2020-01-01Completed
Using Cryoballoon Ablation as Initial Treatment for Patients With Persistent Atrial Fibrillation Comparing to Anti-arrhythmic Drugs [NCT04942834]286 participants (Anticipated)Interventional2021-08-31Not yet recruiting
A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs [NCT02347111]Phase 4162 participants (Anticipated)Interventional2020-12-31Recruiting
Multicenter Clinical Study of Therapeutic Effect of Sotalol on Children With Arrhythmia (Paroxysmal Supraventricular Tachycardia, Paroxysmal Atrial Tachycardia, Ventricular Tachycardia, Idiopathic Ventricular Tachycardia, Premature Ventricular Contraction [NCT03895411]Phase 4500 participants (Anticipated)Interventional2019-08-31Not yet recruiting
Prospective Evaluation Analysis and Kinetics of IV Sotalol [NCT05247320]167 participants (Actual)Observational2022-02-04Completed
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication [NCT05939076]Phase 3220 participants (Anticipated)Interventional2023-08-21Not yet recruiting
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04757584]Phase 49 participants (Actual)Interventional2021-04-01Completed
[NCT01780311]Phase 40 participants Interventional2013-01-31Recruiting
[NCT00000556]Phase 30 participants Interventional1995-03-31Completed
[NCT00000531]Phase 30 participants Interventional1992-09-30Completed
CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation [NCT00007605]Phase 3706 participants (Anticipated)Interventional1998-04-30Completed
SLR/NMA of Multaq® vs Sotalol to Assess for Safety in Patients With Atrial Fibrillation (AFib) [NCT05279833]87,810 participants (Actual)Observational2021-09-24Completed
Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study. [NCT02303639]Phase 4120 participants (Anticipated)Interventional2015-04-30Recruiting
Safety Assessment for Sotalol Protocol in Outpatient Unit [NCT05418036]Phase 4110 participants (Anticipated)Interventional2020-10-26Recruiting
[NCT00257959]Phase 4400 participants Interventional2001-01-31Completed
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol [NCT05794997]817,337 participants (Actual)Observational2022-11-30Active, not recruiting
A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation [NCT00540787]Phase 4112 participants (Actual)Interventional2003-08-31Completed
[NCT00000464]Phase 30 participants Interventional1987-04-30Completed
[NCT00000518]Phase 30 participants Interventional1985-07-31Completed
A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation [NCT02389218]Phase 413 participants (Actual)Interventional2015-03-03Completed
Early Aggressive Invasive Intervention for Atrial Fibrillation [NCT02825979]303 participants (Actual)Interventional2017-01-31Active, not recruiting
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation. [NCT00035451]Phase 3658 participants (Actual)Interventional2001-02-28Completed
Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed) [NCT01798277]Phase 30 participants (Actual)Interventional2013-04-30Withdrawn(stopped due to Low Enrolment)
Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation [NCT02459574]300 participants (Anticipated)Interventional2015-05-01Completed
Ventricular Tachycardia Antiarrhythmics or AblatioN In Structural Heart Disease 2 [NCT02830360]Phase 4416 participants (Actual)Interventional2016-10-31Active, not recruiting
Progression of Atrial Fibrillation After a Failed Initial Ablation Procedure in Patients With Paroxysmal Atrial Fibrillation: A Randomized Comparison of the Drug Therapy Versus Re-Ablation [NCT01709682]Phase 2154 participants (Actual)Interventional2007-11-30Completed
A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker [NCT02153437]Phase 17 participants (Actual)Interventional2014-10-30Terminated
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients [NCT04128878]12 participants (Actual)Observational2019-05-01Completed
Elimination of Ventricular Premature Beats With CaTheter Ablation Versus OPtImal Anti-arrhythmic Drug Treatment [NCT03845010]22 participants (Actual)Interventional2019-02-12Completed
FAST RCT: Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy [NCT02624765]Phase 3600 participants (Anticipated)Interventional2016-02-29Recruiting
A Randomized Trial to Assess the Utility of Empirical Anti-Arrhythmic Drug Therapy to Prevent Atrial Arrhythmia During the 6 Weeks Following Pulmonary Vein Isolation to Treat Paroxysmal Atrial Fibrillation [NCT00408200]110 participants (Actual)Interventional2006-11-30Completed
Continuation of Antiarrhythmics Following caThEteR Ablation for Ventricular Tachycardia (AFTER-VT) Trial: A Pilot Randomized Clinical Trial [NCT04208997]Phase 35 participants (Actual)Interventional2019-12-19Terminated(stopped due to Study was terminated due to low accrual)
Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL [NCT01576042]27 participants (Actual)Interventional2012-05-31Terminated(stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00408200 (2) [back to overview]Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug
NCT00408200 (2) [back to overview]Freedom From Atrial Arrhythmia at 6 Months Post Procedure.
NCT00523978 (5) [back to overview]Acute Procedural Success (APS)
NCT00523978 (5) [back to overview]Cryoablation Procedure Events (CPEs)
NCT00523978 (5) [back to overview]Freedom From Chronic Treatment Failure (CTF)
NCT00523978 (5) [back to overview]Freedom From Major Atrial Fibrillation Events (MAFEs)
NCT00523978 (5) [back to overview]Treatment Success
NCT01576042 (8) [back to overview]Cardiovascular Hospitalizations
NCT01576042 (8) [back to overview]Number of Participants Completed Month 3 Follow-Up
NCT01576042 (8) [back to overview]Number of Participants Completed Month 6 Follow-Up
NCT01576042 (8) [back to overview]Number of Participants Had at Least One of the Efficacy Outcome Measurement
NCT01576042 (8) [back to overview]Number of Participants Received Treatment Assigned
NCT01576042 (8) [back to overview]Number of Participants Remained on Randomized Treatment Assignment
NCT01576042 (8) [back to overview]Number of Participants Switched to Other Arm
NCT01576042 (8) [back to overview]Time to First Recurrent ICD Therapy for VT
NCT04208997 (6) [back to overview]All-cause Mortality
NCT04208997 (6) [back to overview]Number of Participants Dead or With VT Recurrence at One Year
NCT04208997 (6) [back to overview]Number of Participants With Drug Side Effects
NCT04208997 (6) [back to overview]Number of Participants With Readmission for Heart Failure
NCT04208997 (6) [back to overview]Number of Participants With VT Recurrence
NCT04208997 (6) [back to overview]Number of Participants With VT/Electrical Storm
NCT04767061 (10) [back to overview]Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)
NCT04767061 (10) [back to overview]Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
NCT04767061 (10) [back to overview]Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)
NCT04767061 (10) [back to overview]Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)
NCT04767061 (10) [back to overview]Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device
NCT04767061 (10) [back to overview]Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug

(NCT00408200)
Timeframe: 6 weeks

Interventionparticipants (Number)
AAD:NO24
AAD:YES10

[back to top]

Freedom From Atrial Arrhythmia at 6 Months Post Procedure.

(NCT00408200)
Timeframe: 6 weeks

Interventionparticipants (Number)
AAD:NO39
AAD:YES35

[back to top]

Acute Procedural Success (APS)

Acute Procedural Success was defined as a demonstration of electrical isolation in ≥ 3 Pulmonary Veins (PVs) at the conclusion of the first protocol-defined cryoablation procedure. APS was decided at the end of the procedure the mean time was calculated for the time frame. (NCT00523978)
Timeframe: 371.4 Minutes (Average)

Interventionparticipants (Number)
Cryoablation160

[back to top]

Cryoablation Procedure Events (CPEs)

Subjects that had CPEs. CPEs were device- or procedure-related serious adverse events (SAE) categorized as access site complications, cardiac damage, pulmonary vein (PV) stenosis, embolic complications, arrhythmias, unresolved phrenic nerve palsy and death. (NCT00523978)
Timeframe: To end of ablation procedure

Interventionparticipants (Number)
Cryoablation5

[back to top]

Freedom From Chronic Treatment Failure (CTF)

Subjects that did not have or were free of CTF. CTF was defined as the occurence of an Atrial Fibrillation (AF) intervention, use of non-study AF drug therapy, or the occurence of detectable AF which is is defined as an episode of AF, documented in a tracing, and lasting more than 30 seconds, occurring during a Non Blanked Follow-up Period. (NCT00523978)
Timeframe: 12 month follow up period

Interventionparticipants (Number)
Cryoablation117
Standard Treatment With Drugs Only6

[back to top]

Freedom From Major Atrial Fibrillation Events (MAFEs)

Subjects that did not have or were free of MAFEs. MAFEs were serious adverse events categorized as cardiovascular death, myocardial infarction, stroke, or hospitalization for AF recurrence/ablation, flutter ablation, embolic events, heart failure, hemorrhage or anti-arrhythmic drug treatment. (NCT00523978)
Timeframe: 12 Months

Interventionparticipants (Number)
Cryoablation158
Standard Treatment With Drugs Only75

[back to top]

Treatment Success

Treatment Success was defined as Acute Procedure Success (APS) and freedom from Chronic Treatment Failure (CTF) for Experimental Subjects, and freedom from CTF for Control Subjects. Under this pre-specified definition of Treatment Success, Experimental Subjects must have had APS and remained free of CTF during the 12-month follow-up duration, while Control Subjects must have remained free of CTF during the 12-month follow-up duration. (NCT00523978)
Timeframe: 12 months

Interventionparticipants (Number)
Cryoablation114
Standard Treatment With Drugs Only6

[back to top]

Cardiovascular Hospitalizations

Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months

Interventionparticipants (Number)
Catheter Ablation5
Antiarrhythmic Medication7

[back to top]

Number of Participants Completed Month 3 Follow-Up

Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months

Interventionparticipants (Number)
Catheter Ablation11
Antiarrhythmic Medication12

[back to top]

Number of Participants Completed Month 6 Follow-Up

Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months

Interventionparticipants (Number)
Catheter Ablation7
Antiarrhythmic Medication10

[back to top]

Number of Participants Had at Least One of the Efficacy Outcome Measurement

Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months

Interventionparticipants (Number)
Catheter Ablation11
Antiarrhythmic Medication14

[back to top]

Number of Participants Received Treatment Assigned

Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months

Interventionparticipants (Number)
Catheter Ablation11
Antiarrhythmic Medication14

[back to top]

Number of Participants Remained on Randomized Treatment Assignment

Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month

Interventionparticipants (Number)
Catheter Ablation6
Antiarrhythmic Medication13

[back to top]

Number of Participants Switched to Other Arm

Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months

Interventionparticipants (Number)
Catheter Ablation5
Antiarrhythmic Medication1

[back to top]

Time to First Recurrent ICD Therapy for VT

Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months

InterventionDays (Mean)
Catheter Ablation70.1
Antiarrhythmic Medication78.7

[back to top]

All-cause Mortality

Deaths by any cause one year after ablation (NCT04208997)
Timeframe: One year after ablation

InterventionParticipants (Count of Participants)
Continuation of Antiarrhythmic Drugs0
Discontinuation of Antiarrhythmic Drugs0

[back to top]

Number of Participants Dead or With VT Recurrence at One Year

A composite of all-cause mortality and VT recurrence one year after index VT ablation (NCT04208997)
Timeframe: One year after ablation

InterventionParticipants (Count of Participants)
Continuation of Antiarrhythmic Drugs0
Discontinuation of Antiarrhythmic Drugs0

[back to top]

Number of Participants With Drug Side Effects

Side effects attributed to any drug of the patient's regimen (NCT04208997)
Timeframe: One year after ablation

InterventionParticipants (Count of Participants)
Continuation of Antiarrhythmic Drugs1
Discontinuation of Antiarrhythmic Drugs0

[back to top]

Number of Participants With Readmission for Heart Failure

Admissions with heart failure as principal diagnosis (NCT04208997)
Timeframe: One year after ablation

InterventionParticipants (Count of Participants)
Continuation of Antiarrhythmic Drugs0
Discontinuation of Antiarrhythmic Drugs0

[back to top]

Number of Participants With VT Recurrence

Self-terminating sustained VTs (>30 seconds or hemodynamic instability) and VT requiring ICD device therapies for termination (appropriate therapies) will be considered VT recurrences (NCT04208997)
Timeframe: One year after ablation

InterventionParticipants (Count of Participants)
Continuation of Antiarrhythmic Drugs0
Discontinuation of Antiarrhythmic Drugs0

[back to top]

Number of Participants With VT/Electrical Storm

Three or more episodes of sustained VT, ventricular fibrillation, or appropriate ICD therapies within a 24-hour period (NCT04208997)
Timeframe: One year after ablation

InterventionParticipants (Count of Participants)
Continuation of Antiarrhythmic Drugs0
Discontinuation of Antiarrhythmic Drugs0

[back to top]

Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)

"Cardiopulmonary exercise testing (CPET) measures breath-by-breath oxygen production during symptom-limited exercise on a stationary bike. This permits the calculation of peak oxygen consumption (VO2). Percent predicted peak VO2 for body weight will also be calculated. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 6-weeks. This outcome was measured at the end of the first and second visit.

Interventionml/kg/min (Mean)
ON Beta Blockers10.0
OFF Beta Blockers11.4

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The balance test portion of the SPPB assesses the subject's ability to stand unassisted without the use of a cane or walker. Balance test scores range from 0 - 4 with higher scores indicating better ability to stand unassisted. Our research team conducted the balance test according to SPPB standards. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers3.9
OFF Beta Blockers3.6

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The chair rise portion of the SPPB assesses core strength. When comparing the number of seconds it takes to complete 5 chair rises, quicker speeds indicate better core strength. Our research team has chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers16
OFF Beta Blockers15.1

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The gait speed portion of the SPPB assesses the subject's lower extremity function. When comparing the number of seconds it takes to complete the 4-meter gait speed test, quicker speeds indicate better lower extremity function. Our research team conducted the 4-meter gait speed test according to SPPB standards, but have chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers4.3
OFF Beta Blockers4.6

[back to top]

Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)

"Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a) is a survey of patient-perceived cognitive deficits. Questions are ranked on a 5-point Likert scale, with higher scores indicating better cognitive function. Scores are mapped so the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse cognitive function compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3-6 weeks. The outcome measure data is the mean of the data collected during the span of the measured time points." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers53.8
OFF Beta Blockers52.4

[back to top]

Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

"The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. Questions are ranked on 5- to 7-point Likert scales, with higher scores indicating better health status. KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The max amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, bi-weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers58.7
OFF Beta Blockers66.0

[back to top]

Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)

"The EuroQol-5D Visual Analogue System (EQ-5D VAS) indicates patient-perceived health on a vertical visual analogue scale. The scale ranges from 0, indicating poorest health, to 100, indicating the best health. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers68.9
OFF Beta Blockers67.8

[back to top]

Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

"Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function) measures self-reported sexual function and satisfaction. Questions are ranked on a 6-point Likert scale, with higher scores indicating poorer sexual function and satisfaction. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame. The score ranges from 0-10 with higher scores meaning worsened sexual function." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers1.8
OFF Beta Blockers2.1

[back to top]

Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device

"The wearable activity monitoring device measures daily step count. Due to the nature of N-of-1 trials, the duration of a subject's periods varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 and 6 weeks. We will compare average step counts over 2-week periods, which will be the final 2 weeks of each period when subjects are either on their home (ON Beta Blockers) or minimally tolerated (OFF Beta Blockers) dose. The outcome measure data is the mean collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 8-weeks (last 2 weeks of each period for up to 4 periods).

InterventionCount of Steps (Mean)
ON Beta Blockers2790.5
OFF Beta Blockers3167.3

[back to top]

Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

"The PROMIS-29 assesses 7 domains with 4 questions with an additional pain intensity numeric rating scale. The patients' answers to the PROMIS-29 are scored from 1-5 (except for the pain numeric rating scale). The sum of the PROMIS-29 is the raw score transformed into a final T-score metric. Scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the PROMIS-29 raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse health compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker before enrollment, therefore, each subject's respective period for the OFF and ON periods could range between 3 - 6 weeks. The values measured over the time points were averaged." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

,
Interventionscore on a scale (Mean)
Physical Health ComponentMental Health Component
OFF Beta Blockers40.047.9
ON Beta Blockers39.846.8

[back to top]